Regulation	O
of	O
the	O
balance	O
of	O
cytokine	B-protein
production	O
and	O
the	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	B-protein
)	O
transcription	O
factor	O
activity	O
by	O
cytokines	B-protein
and	O
inflammatory	O
synovial	O
fluids	O
.	O

The	O
balance	O
between	O
type	O
1	O
and	O
2	O
T	O
helper	O
cell	O
cytokine	O
production	O
plays	O
an	O
important	O
role	O
in	O
several	O
animal	O
models	O
of	O
autoimmunity	O
,	O
and	O
skewed	O
patterns	O
of	O
cytokine	B-protein
expression	O
have	O
been	O
described	O
in	O
human	O
inflammatory	O
diseases	O
.	O

Many	O
cytokines	B-protein
activate	O
signal	B-protein
transducer	I-protein
and	I-protein
activation	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
transcription	I-protein
factors	I-protein
,	O
which	O
,	O
in	O
turn	O
,	O
activate	O
transcription	O
of	O
inflammatory	O
effector	O
genes	O
.	O

We	O
used	O
mononuclear	B-cell_line
cell	I-cell_line
priming	I-cell_line
cultures	I-cell_line
and	O
inflammatory	B-cell_type
synovial	I-cell_type
fluids	I-cell_type
(	O
SFs	B-cell_type
)	O
derived	O
from	O
arthritis	O
patients	O
to	O
examine	O
the	O
regulation	O
of	O
cytokine	B-protein
production	O
and	O
STAT	B-protein
activity	O
by	O
an	O
inflammatory	O
synovial	O
microenvironment	O
.	O

Exposure	O
to	O
SFs	B-cell_type
during	O
priming	O
resulted	O
in	O
an	O
81	O
%	O
inhibition	O
of	O
interferon	B-protein
(	I-protein
IFN	I-protein
)	I-protein
-gamma	I-protein
,	O
but	O
not	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
4	I-protein
,	O
production	O
by	O
effector	B-cell_type
cells	I-cell_type
generated	O
in	O
priming	O
cultures	O
.	O

SF	O
suppression	O
was	O
mediated	O
by	O
IL-4	B-protein
and	O
IL-10	B-protein
and	O
inhibition	O
of	O
IL-12	B-protein
expression	O
,	O
and	O
it	O
was	O
reversed	O
in	O
a	O
dominant	O
fashion	O
by	O
exogenous	O
IL-12	O
.	O

SFs	B-cell_type
blocked	O
the	O
sustained	O
activity	O
of	O
transcription	B-protein
factor	I-protein
Stat1	I-protein
,	O
but	O
not	O
Stat3	B-protein
,	O
during	O
the	O
priming	O
period	O
,	O
and	O
Stat1	B-protein
activity	O
was	O
differentially	O
regulated	O
by	O
cytokines	B-protein
in	O
parallel	O
with	O
their	O
positive	O
or	O
negative	O
regulation	O
of	O
IFN-gamma	B-protein
production	O
.	O

Active	O
Stat3	B-protein
,	O
but	O
not	O
Stat1	B-protein
,	O
was	O
detected	O
in	O
cells	O
from	O
inflamed	O
joints	O
.	O

These	O
results	O
suggest	O
a	O
role	O
for	O
altered	O
balance	O
of	O
Stat1	O
and	O
Stat3	O
transcriptional	O
activity	O
in	O
the	O
regulation	O
of	O
T	B-cell_type
cell	I-cell_type
differentiation	O
and	O
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
synovitis	O
.	O

Regulation	NULL
of	NULL
the	NULL
Balance	NULL
of	NULL
Cytokine	NULL
Production	NULL
and	NULL
the	NULL
Signal	NULL
Transducer	NULL
and	NULL
Activator	NULL
of	NULL
Transcription	NULL
(	NULL
STAT	NULL
)	NULL
Transcription	NULL
Factor	NULL
Activity	NULL
by	NULL
Cytokines	NULL
and	NULL
Inflammatory	NULL
Synovial	NULL
Fluids	NULL
By	NULL
Fushen	NULL
Wang	NULL
,	NULL
*	NULL
Tapas	NULL
K.	NULL
Sengupta	NULL
,	NULL
*	NULL
Zhong	NULL
Zhong	NULL
,	NULL
$	NULL
and	NULL
Lionel	NULL
B.	NULL
Ivushkiv*t	NULL
From	NULL
the	NULL
*Department	NULL
of	NULL
Medicine	NULL
,	NULL
Hospital	NULL
for	NULL
Special	NULL
Surgery	NULL
,	NULL
and	NULL
the	NULL
*Graduate	NULL
Program	NULL
in	NULL
Immunology	NULL
,	NULL
Cornell	NULL
University	NULL
Graduate	NULL
School	NULL
of	NULL
Medical	NULL
Sciences	NULL
,	NULL
New	NULL
York	NULL
10021	NULL
;	NULL
and	NULL
$	NULL
Laboratory	NULL
of	NULL
Molecular	NULL
Cell	NULL
Biology	NULL
,	NULL
The	NULL
Rockefeller	NULL
University	NULL
,	NULL
New	NULL
York	NULL
10021	NULL
Summary	NULL
The	NULL
balance	NULL
between	NULL
type	NULL
1	NULL
and	NULL
2	NULL
T	NULL
helper	NULL
cell	NULL
cytokine	NULL
production	NULL
plays	NULL
an	NULL
important	NULL
role	NULL
in	NULL
several	NULL
animal	NULL
models	NULL
of	NULL
autoimmunity	NULL
,	NULL
and	NULL
skewed	NULL
patterns	NULL
of	NULL
cytokine	NULL
expression	NULL
have	NULL
been	NULL
described	NULL
in	NULL
human	NULL
inflammatory	NULL
diseases	NULL
.	NULL

Many	NULL
cytokines	NULL
activate	NULL
signal	NULL
transducer	NULL
and	NULL
activation	NULL
of	NULL
transcription	NULL
(	NULL
STAT	NULL
)	NULL
transcription	NULL
factors	NULL
,	NULL
which	NULL
,	NULL
in	NULL
turn	NULL
,	NULL
activate	NULL
transcription	NULL
of	NULL
inflammatory	NULL
effector	NULL
genes	NULL
.	NULL

We	NULL
used	NULL
mononuclear	NULL
cell	NULL
priming	NULL
cultures	NULL
and	NULL
inflammatory	NULL
synovial	NULL
fluids	NULL
(	NULL
SFs	NULL
)	NULL
derived	NULL
from	NULL
arthritis	NULL
patients	NULL
to	NULL
examine	NULL
the	NULL
regulation	NULL
of	NULL
cytokine	NULL
production	NULL
and	NULL
STAT	NULL
activity	NULL
by	NULL
an	NULL
inflammatory	NULL
synovial	NULL
microenvironment	NULL
.	NULL

Exposure	NULL
to	NULL
SFs	NULL
during	NULL
priming	NULL
resulted	NULL
in	NULL
an	NULL
81	NULL
%	NULL
inhibition	NULL
of	NULL
interferon	NULL
(	NULL
IFN	NULL
)	NULL
-y	NULL
,	NULL
but	NULL
not	NULL
interleukin	NULL
(	NULL
IL	NULL
)	NULL
4	NULL
,	NULL
production	NULL
by	NULL
effector	NULL
cells	NULL
generated	NULL
in	NULL
priming	NULL
cultures	NULL
.	NULL

SF	NULL
suppression	NULL
was	NULL
mediated	NULL
by	NULL
IL-4	NULL
and	NULL
IL-10	NULL
and	NULL
inhibition	NULL
of	NULL
IL-12	NULL
expression	NULL
,	NULL
and	NULL
it	NULL
was	NULL
reversed	NULL
in	NULL
a	NULL
dominant	NULL
fashion	NULL
by	NULL
exogenous	NULL
IL-12	NULL
.	NULL

SFs	NULL
blocked	NULL
the	NULL
sustained	NULL
activity	NULL
of	NULL
transcription	NULL
factor	NULL
Stat1	NULL
,	NULL
but	NULL
not	NULL
Stat3	NULL
,	NULL
during	NULL
the	NULL
priming	NULL
period	NULL
,	NULL
and	NULL
Stat1	NULL
activity	NULL
was	NULL
differentially	NULL
regulated	NULL
by	NULL
cytokines	NULL
in	NULL
parallel	NULL
with	NULL
their	NULL
positive	NULL
or	NULL
negative	NULL
regulation	NULL
of	NULL
IFN-y	NULL
production	NULL
.	NULL

Active	NULL
Stat3	NULL
,	NULL
but	NULL
not	NULL
Stat1	NULL
,	NULL
was	NULL
detected	NULL
in	NULL
cells	NULL
from	NULL
inflamed	NULL
joints	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
a	NULL
role	NULL
for	NULL
altered	NULL
balance	NULL
of	NULL
Stat1	NULL
and	NULL
Stat3	NULL
transcriptional	NULL
activity	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
T	NULL
cell	NULL
differentiation	NULL
and	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
in	NULL
flammatory	NULL
synovitis	NULL
.	NULL

Activation	NULL
of	NULL
cells	NULL
and	NULL
subsequent	NULL
secretion	NULL
of	NULL
cytokines	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
autoimmune	NULL
and	NULL
inflammatory	NULL
diseases	NULL
.	NULL

Predominant	NULL
expression	NULL
of	NULL
either	NULL
Th1	NULL
(	NULL
IFN-y	NULL
and	NULL
lymphotoxin	NULL
)	NULL
or	NULL
Th2	NULL
(	NULL
IL-4	NULL
,	NULL
IL-5	NULL
,	NULL
IL-6	NULL
,	NULL
and	NULL
IL-10	NULL
)	NULL
cytokines	NULL
has	NULL
been	NULL
associated	NULL
with	NULL
active	NULL
inflammation	NULL
(	NULL
1	NULL
)	NULL
.	NULL

For	NULL
example	NULL
,	NULL
Th1	NULL
cytokines	NULL
contribute	NULL
to	NULL
the	NULL
pathogenesis	NULL
of	NULL
experimental	NULL
allergic	NULL
encephalitis	NULL
(	NULL
2	NULL
)	NULL
and	NULL
collagen-induced	NULL
arthritis	NULL
(	NULL
3	NULL
)	NULL
,	NULL
whereas	NULL
elevated	NULL
Th2	NULL
cytokine	NULL
production	NULL
has	NULL
been	NULL
associated	NULL
with	NULL
inflammatory	NULL
bowel	NULL
disease	NULL
(	NULL
4	NULL
)	NULL
,	NULL
autoan-tibody	NULL
production	NULL
(	NULL
5	NULL
)	NULL
,	NULL
and	NULL
chronic	NULL
arthritis	NULL
associated	NULL
with	NULL
the	NULL
caprine	NULL
arthritis-encephalitis	NULL
virus	NULL
(	NULL
CAEV	NULL
)	NULL
!	NULL

(	NULL
6	NULL
)	NULL
.	NULL

Patterns	NULL
of	NULL
cytokine	NULL
expression	NULL
during	NULL
an	NULL
immune	NULL
response	NULL
are	NULL
controlled	NULL
by	NULL
a	NULL
complex	NULL
regulatory	NULL
network	NULL
that	NULL
uses	NULL
cytokines	NULL
and	NULL
factors	NULL
derived	NULL
from	NULL
accessory	NULL
cells	NULL
and	NULL
T	NULL
cells	NULL
(	NULL
7	NULL
)	NULL
.	NULL

IL-12	NULL
and	NULL
IFN-y	NULL
are	NULL
the	NULL
primary	NULL
stimulators	NULL
of	NULL
Th1	NULL
responses	NULL
,	NULL
whereas	NULL
Th2	NULL
cytokine	NULL
production	NULL
is	NULL
stimulated	NULL
by	NULL
IL-4	NULL
,	NULL
IL-10	NULL
,	NULL
and	NULL
E	NULL
series	NULL
prostaglandins	NULL
(	NULL
PGEs	NULL
)	NULL
.	NULL

There	NULL
is	NULL
little	NULL
in	NULL
'	NULL
Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
CAEV	NULL
,	NULL
caprine	NULL
arthritis-encephalitis	NULL
virus	NULL
;	NULL
CM	NULL
,	NULL
complete	NULL
medium	NULL
;	NULL
MNC	NULL
,	NULL
mononuclear	NULL
cell	NULL
;	NULL
mRNA	NULL
,	NULL
messenger	NULL
RNA	NULL
;	NULL
PGE	NULL
,	NULL
E	NULL
series	NULL
prostaglandin	NULL
;	NULL
SF	NULL
,	NULL
synovial	NULL
fluid	NULL
;	NULL
SIF	NULL
,	NULL
serum-inducible	NULL
factor	NULL
;	NULL
STAT	NULL
,	NULL
signal	NULL
transductors	NULL
and	NULL
activators	NULL
of	NULL
transcription	NULL
.	NULL

1825	NULL
formation	NULL
available	NULL
concerning	NULL
which	NULL
of	NULL
these	NULL
factors	NULL
is	NULL
important	NULL
in	NULL
regulating	NULL
cytokine	NULL
expression	NULL
in	NULL
inflammatory	NULL
diseases	NULL
.	NULL

Many	NULL
cytokines	NULL
that	NULL
regulate	NULL
immune	NULL
responses	NULL
activate	NULL
specific	NULL
members	NULL
of	NULL
the	NULL
STAT	NULL
(	NULL
signal	NULL
transducers	NULL
and	NULL
activators	NULL
of	NULL
transcription	NULL
)	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
(	NULL
8	NULL
,	NULL
9	NULL
)	NULL
.	NULL

STAT	NULL
's	NULL
exhibit	NULL
differential	NULL
binding	NULL
to	NULL
target	NULL
sequences	NULL
present	NULL
in	NULL
gene	NULL
promoters	NULL
,	NULL
and	NULL
the	NULL
pattern	NULL
of	NULL
STAT	NULL
's	NULL
that	NULL
become	NULL
activated	NULL
determines	NULL
,	NULL
at	NULL
least	NULL
in	NULL
part	NULL
,	NULL
patterns	NULL
of	NULL
gene	NULL
expression	NULL
and	NULL
the	NULL
phenotype	NULL
of	NULL
activated	NULL
cells	NULL
.	NULL

In	NULL
experiments	NULL
using	NULL
cell	NULL
lines	NULL
,	NULL
purified	NULL
cytokines	NULL
preferentially	NULL
activate	NULL
particular	NULL
STAT	NULL
's	NULL
by	NULL
inducing	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
STAT	NULL
's	NULL
by	NULL
cytokine	NULL
receptor-associated	NULL
Jak	NULL
kinases	NULL
.	NULL

For	NULL
example	NULL
,	NULL
IFN-y	NULL
preferentially	NULL
activates	NULL
Stat1	NULL
,	NULL
and	NULL
IL-6	NULL
preferentially	NULL
activates	NULL
Stat3	NULL
(	NULL
8	NULL
)	NULL
.	NULL

However	NULL
,	NULL
regulation	NULL
of	NULL
STAT	NULL
's	NULL
in	NULL
a	NULL
more	NULL
physiological	NULL
setting	NULL
is	NULL
more	NULL
complex	NULL
and	NULL
may	NULL
involve	NULL
regulation	NULL
of	NULL
STAT	NULL
dephosphorylation	NULL
(	NULL
10	NULL
)	NULL
and	NULL
serine	NULL
phosphorylation	NULL
(	NULL
11	NULL
)	NULL
as	NULL
well	NULL
as	NULL
regulation	NULL
of	NULL
Jak	NULL
kinase	NULL
activity	NULL
by	NULL
additional	NULL
ligands	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
pattern	NULL
of	NULL
activated	NULL
STAT	NULL
's	NULL
may	NULL
reveal	NULL
information	NULL
about	NULL
integrated	NULL
cellular	NULL
responses	NULL
to	NULL
multiple	NULL
ligands	NULL
.	NULL

Chronic	NULL
inflammatory	NULL
arthritis	NULL
(	NULL
synovitis	NULL
)	NULL
in	NULL
humans	NULL
rep	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

©	NULL
The	NULL
Rockefeller	NULL
University	NULL
Press	NULL
+	NULL
0022-1007/95/12/1825/07	NULL
$	NULL
2.00	NULL
Volume	NULL
182	NULL
December	NULL
1995	NULL
1825-1831	NULL
resents	NULL
an	NULL
intensively	NULL
studied	NULL
process	NULL
in	NULL
which	NULL
multiple	NULL
cytokines	NULL
are	NULL
expressed	NULL
and	NULL
are	NULL
likely	NULL
to	NULL
contribute	NULL
to	NULL
pathogenesis	NULL
(	NULL
13	NULL
)	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
high	NULL
levels	NULL
of	NULL
Th2	NULL
cytokines	NULL
and	NULL
regulators	NULL
,	NULL
such	NULL
as	NULL
IL-10	NULL
,	NULL
PGEs	NULL
,	NULL
and	NULL
TGF-B	NULL
,	NULL
coupled	NULL
with	NULL
the	NULL
low	NULL
levels	NULL
of	NULL
IFN-y	NULL
protein	NULL
in	NULL
actively	NULL
inflamed	NULL
joints	NULL
(	NULL
13-17	NULL
)	NULL
,	NULL
suggests	NULL
that	NULL
down-regulation	NULL
of	NULL
Th1	NULL
cytokines	NULL
may	NULL
occur	NULL
during	NULL
synovitis	NULL
(	NULL
16	NULL
)	NULL
.	NULL

We	NULL
studied	NULL
the	NULL
regulation	NULL
of	NULL
cytokine	NULL
production	NULL
and	NULL
STAT	NULL
activity	NULL
using	NULL
an	NULL
in	NULL
vitro	NULL
priming	NULL
system	NULL
in	NULL
which	NULL
mononuclear	NULL
cells	NULL
(	NULL
MNC	NULL
)	NULL
from	NULL
peripheral	NULL
blood	NULL
are	NULL
exposed	NULL
to	NULL
synovial	NULL
fluids	NULL
(	NULL
SFs	NULL
)	NULL
from	NULL
patients	NULL
with	NULL
inflammatory	NULL
arthritis	NULL
.	NULL

The	NULL
aim	NULL
is	NULL
to	NULL
reproduce	NULL
existing	NULL
conditions	NULL
when	NULL
blood	NULL
mononuclear	NULL
cells	NULL
enter	NULL
an	NULL
inflamed	NULL
joint	NULL
and	NULL
are	NULL
exposed	NULL
to	NULL
a	NULL
complex	NULL
inflammatory	NULL
microenvironment	NULL
.	NULL

Culture	NULL
with	NULL
SFs	NULL
resulted	NULL
in	NULL
the	NULL
inhibition	NULL
of	NULL
Stat1	NULL
activity	NULL
,	NULL
with	NULL
concomitant	NULL
polarization	NULL
of	NULL
cytokine	NULL
production	NULL
toward	NULL
a	NULL
Th2	NULL
pheno-	NULL
type	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Cell	NULL
Culture	NULL
and	NULL
Flow	NULL
Cytometry	NULL
.	NULL

-	NULL
Ficoll	NULL
density	NULL
gradient-puri-fied	NULL
peripheral	NULL
blood	NULL
MNC	NULL
obtained	NULL
from	NULL
disease-free	NULL
volunteers	NULL
was	NULL
stimulated	NULL
with	NULL
1.3	NULL
ug/ml	NULL
PHA	NULL
in	NULL
complete	NULL
medium	NULL
(	NULL
CM	NULL
;	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
glutamine	NULL
and	NULL
5	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
)	NULL
.	NULL

SFs	NULL
or	NULL
plasma	NULL
controls	NULL
were	NULL
added	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
30	NULL
%	NULL
at	NULL
the	NULL
initiation	NULL
of	NULL
culture	NULL
.	NULL

After	NULL
7	NULL
d	NULL
,	NULL
effector	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
washed	NULL
,	NULL
and	NULL
1.8	NULL
X	NULL
10°	NULL
cells	NULL
were	NULL
restimulated	NULL
in	NULL
CM	NULL
with	NULL
10	NULL
pg/ml	NULL
PHA	NULL
.	NULL

After	NULL
culture	NULL
,	NULL
>	NULL
90	NULL
%	NULL
of	NULL
cells	NULL
were	NULL
viable	NULL
,	NULL
as	NULL
assessed	NULL
by	NULL
trypan	NULL
blue	NULL
and	NULL
propidium	NULL
iodide	NULL
staining	NULL
,	NULL
and	NULL
cell	NULL
surface	NULL
phenotype	NULL
was	NULL
analyzed	NULL
using	NULL
flow	NULL
cytometry	NULL
.	NULL

The	NULL
following	NULL
purified	NULL
mAbs	NULL
were	NULL
used	NULL
.	NULL

T	NULL
cell	NULL
markers	NULL
:	NULL
4B5	NULL
(	NULL
anti-CD3	NULL
)	NULL
,	NULL
13B8.2	NULL
(	NULL
anti-CD4	NULL
)	NULL
,	NULL
and	NULL
B9.11	NULL
(	NULL
anti-CD8	NULL
)	NULL
;	NULL
B	NULL
cells	NULL
:	NULL
J4.119	NULL
(	NULL
anti-CD19	NULL
)	NULL
and	NULL
BlLy.1	NULL
(	NULL
anti-€CD20	NULL
)	NULL
;	NULL
monocytes	NULL
:	NULL
IV.3	NULL
(	NULL
anti-CD32	NULL
monocyte-specific	NULL
epitope	NULL
)	NULL
and	NULL
RMO52	NULL
(	NULL
anti-CD14	NULL
)	NULL
;	NULL
NK	NULL
cells	NULL
:	NULL
3G8	NULL
(	NULL
anti-CD16	NULL
)	NULL
and	NULL
T1.99	NULL
(	NULL
anti-CD56	NULL
)	NULL
.	NULL

mAbs	NULL
were	NULL
purchased	NULL
from	NULL
Amac	NULL
,	NULL
Inc.	NULL
(	NULL
Westbrook	NULL
,	NULL
ME	NULL
)	NULL
,	NULL
except	NULL
for	NULL
4B5	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
Corp.	NULL
,	NULL
Indianapolis	NULL
,	NULL
IN	NULL
)	NULL
and	NULL
IV.3	NULL
(	NULL
Medarex	NULL
,	NULL
New	NULL
Lebanon	NULL
,	NULL
NH	NULL
)	NULL
.	NULL

IgG1	NULL
(	NULL
MOPC	NULL
21	NULL
)	NULL
and	NULL
IgG2a	NULL
(	NULL
UPC10	NULL
)	NULL
isotype	NULL
controls	NULL
were	NULL
obtained	NULL
from	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
(	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
.	NULL

SFs	NULL
.	NULL

-	NULL
SFs	NULL
were	NULL
obtained	NULL
,	NULL
after	NULL
receiving	NULL
informed	NULL
consent	NULL
,	NULL
from	NULL
patients	NULL
with	NULL
seropositive	NULL
definite	NULL
or	NULL
classic	NULL
rheumatoid	NULL
arthritis	NULL
(	NULL
11	NULL
SFs	NULL
)	NULL
,	NULL
or	NULL
with	NULL
chronic	NULL
seronegative	NULL
inflammatory	NULL
arthritis	NULL
(	NULL
6	NULL
SFs	NULL
)	NULL
,	NULL
by	NULL
the	NULL
patients	NULL
'	NULL
physicians	NULL
for	NULL
medically	NULL
indicated	NULL
reasons	NULL
.	NULL

The	NULL
protocol	NULL
for	NULL
obtaining	NULL
research	NULL
samples	NULL
has	NULL
been	NULL
approved	NULL
by	NULL
the	NULL
Institutional	NULL
Review	NULL
Board	NULL
.	NULL

SFs	NULL
were	NULL
handled	NULL
using	NULL
sterile	NULL
technique	NULL
and	NULL
centrifuged	NULL
for	NULL
10	NULL
min	NULL
at	NULL
10,000	NULL
g	NULL
to	NULL
remove	NULL
cells	NULL
and	NULL
particulate	NULL
debris	NULL
;	NULL
aliquots	NULL
were	NULL
stored	NULL
at	NULL
-80°C	NULL
.	NULL

ELISA	NULL
.	NULL

-	NULL
Indirect	NULL
ELISA	NULL
was	NULL
performed	NULL
using	NULL
specific	NULL
mono-clonal	NULL
capture	NULL
antibodies	NULL
anti-IFN-y	NULL
(	NULL
Genzyme	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
)	NULL
and	NULL
MP4-25D2	NULL
(	NULL
anti-IL-4	NULL
;	NULL
PharMingen	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
and	NULL
secondary	NULL
antibodies	NULL
anti-IFN-y	NULL
(	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
,	NULL
Minneapolis	NULL
,	NULL
MN	NULL
)	NULL
and	NULL
8D4.8	NULL
(	NULL
anti-IL-4	NULL
;	NULL
PharMingen	NULL
)	NULL
,	NULL
using	NULL
the	NULL
protocol	NULL
provided	NULL
by	NULL
PharMingen	NULL
.	NULL

All	NULL
samples	NULL
were	NULL
tested	NULL
in	NULL
duplicate	NULL
.	NULL

The	NULL
values	NULL
in	NULL
Table	NULL
1	NULL
represent	NULL
cytokine	NULL
secretion	NULL
per	NULL
10°	NULL
CD3*	NULL
cells	NULL
,	NULL
which	NULL
was	NULL
calculated	NULL
using	NULL
the	NULL
following	NULL
formula	NULL
:	NULL
(	NULL
measured	NULL
cytokine	NULL
secretion	NULL
per	NULL
10°	NULL
MNC	NULL
+	NULL
percentage	NULL
of	NULL
CD3*	NULL
cells	NULL
)	NULL
X	NULL
100	NULL
=	NULL
cytokine	NULL
secretion	NULL
per	NULL
10°	NULL
CD3	NULL
#	NULL
*	NULL
cells	NULL
.	NULL

cDNA	NULL
Preparation	NULL
and	NULL
PCR	NULL
.	NULL

-	NULL
RNA	NULL
was	NULL
prepared	NULL
using	NULL
RNA-zol	NULL
(	NULL
TM	NULL
Cinna	NULL
Scientific	NULL
,	NULL
Friendswood	NULL
,	NULL
TX	NULL
)	NULL
,	NULL
and	NULL
cDNA	NULL
was	NULL
obtained	NULL
using	NULL
1	NULL
pug	NULL
of	NULL
total	NULL
cellular	NULL
RNA	NULL
and	NULL
avian	NULL
myeloblastosis	NULL
virus	NULL
reverse	NULL
transcriptase	NULL
(	NULL
Invitrogen	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

1	NULL
or	NULL
5	NULL
%	NULL
of	NULL
each	NULL
cDNA	NULL
was	NULL
subjected	NULL
to	NULL
25	NULL
(	NULL
glyceraldehyde-3-phosphate	NULL
dehydrogenase	NULL
)	NULL
,	NULL
30	NULL
(	NULL
IL-2	NULL
)	NULL
,	NULL
or	NULL
35	NULL
(	NULL
IL-12	NULL
p40	NULL
)	NULL
cycles	NULL
of	NULL
PCR	NULL
am-plification	NULL
,	NULL
with	NULL
1	NULL
min	NULL
denaturation	NULL
at	NULL
94°C	NULL
,	NULL
1	NULL
min	NULL
annealing	NULL
at	NULL
60°C	NULL
,	NULL
and	NULL
1.5	NULL
min	NULL
extension	NULL
at	NULL
72°C	NULL
.	NULL

The	NULL
GAPDH	NULL
and	NULL
IL-2	NULL
primers	NULL
span	NULL
introns	NULL
and	NULL
corresponds	NULL
to	NULL
primers	NULL
provided	NULL
by	NULL
Stratagene	NULL
(	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
and	NULL
the	NULL
IL-12	NULL
p40	NULL
primer	NULL
sequences	NULL
are	NULL
5	NULL
``	NULL
GAA-GATGGTATCACCTGGAC	NULL
and	NULL
5	NULL
GAAGAAGCTGCTGGT-GTAGT	NULL
.	NULL

PCR	NULL
resulted	NULL
in	NULL
single	NULL
detectable	NULL
amplification	NULL
products	NULL
of	NULL
the	NULL
correct	NULL
size	NULL
containing	NULL
appropriate	NULL
restriction	NULL
sites	NULL
.	NULL

Amplification	NULL
was	NULL
determined	NULL
to	NULL
be	NULL
in	NULL
the	NULL
linear	NULL
range	NULL
by	NULL
using	NULL
serial	NULL
dilutions	NULL
of	NULL
cDNA	NULL
and	NULL
different	NULL
cycle	NULL
numbers	NULL
.	NULL

DNA-binding	NULL
Assays	NULL
.	NULL

-	NULL
Cell	NULL
extracts	NULL
were	NULL
prepared	NULL
,	NULL
and	NULL
8	NULL
pg	NULL
of	NULL
extract	NULL
was	NULL
assayed	NULL
for	NULL
binding	NULL
to	NULL
a	NULL
radiolabeled	NULL
hSIE	NULL
oligonucleotide	NULL
(	NULL
containing	NULL
a	NULL
STAT	NULL
binding	NULL
site	NULL
;	NULL
reference	NULL
18	NULL
)	NULL
or	NULL
to	NULL
a	NULL
control	NULL
Sp1	NULL
oligonucleotide	NULL
using	NULL
gel	NULL
shift	NULL
assays	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
17	NULL
,	NULL
18	NULL
)	NULL
.	NULL

Results	NULL
SFs	NULL
Skew	NULL
Cytokine	NULL
Production	NULL
toward	NULL
a	NULL
Th2	NULL
Pattern	NULL
.	NULL

-	NULL
Priming	NULL
of	NULL
lymphocytes	NULL
or	NULL
MNC	NULL
results	NULL
in	NULL
the	NULL
generation	NULL
of	NULL
effector	NULL
cells	NULL
that	NULL
exhibit	NULL
an	NULL
enhanced	NULL
capacity	NULL
to	NULL
produce	NULL
both	NULL
Th1	NULL
and	NULL
Th2	NULL
cytokines	NULL
.	NULL

Addition	NULL
of	NULL
regulatory	NULL
factors	NULL
during	NULL
the	NULL
priming	NULL
period	NULL
results	NULL
in	NULL
skewing	NULL
of	NULL
cytokine	NULL
production	NULL
toward	NULL
a	NULL
Th1	NULL
or	NULL
Th2	NULL
pattern	NULL
(	NULL
7	NULL
)	NULL
.	NULL

Table	NULL
1	NULL
shows	NULL
the	NULL
MNC	NULL
cell	NULL
surface	NULL
phenotype	NULL
and	NULL
cytokine	NULL
production	NULL
,	NULL
in	NULL
our	NULL
system	NULL
,	NULL
before	NULL
and	NULL
after	NULL
7	NULL
d	NULL
of	NULL
priming	NULL
culture	NULL
.	NULL

Priming	NULL
was	NULL
effective	NULL
,	NULL
because	NULL
restimulation	NULL
of	NULL
effector	NULL
cells	NULL
,	NULL
which	NULL
were	NULL
predominantly	NULL
lymphocytes	NULL
,	NULL
on	NULL
day	NULL
7	NULL
resulted	NULL
in	NULL
sevenfold	NULL
more	NULL
IFN-y	NULL
production	NULL
and	NULL
11-fold	NULL
Table	NULL
1	NULL
.	NULL

-	NULL
Cytokine	NULL
Secretion	NULL
and	NULL
Phenotype	NULL
of	NULL
Primed	NULL
Blood	NULL
Mononuclear	NULL
Cells	NULL
IFN-y	NULL
IL-4	NULL
CD3+	NULL
CD4+	NULL
CD19+	NULL
CD3*	NULL
or	NULL
CD19+*	NULL
pg/ml	NULL
%	NULL
Fresh	NULL
MNC	NULL
420	NULL
+	NULL
40	NULL
30	NULL
£	NULL
10	NULL
54	NULL
+	NULL
5	NULL
40	NULL
1	NULL
6	NULL
11	NULL
1	NULL
2	NULL
68	NULL
+1	NULL
6	NULL
Primed	NULL
MNC	NULL
2,900	NULL
+	NULL
840	NULL
340	NULL
+	NULL
130	NULL
78	NULL
+	NULL
3	NULL
58	NULL
t	NULL
4	NULL
14	NULL
*	NULL
2	NULL
94	NULL
+	NULL
4	NULL
(	NULL
day	NULL
7	NULL
)	NULL
Freshly	NULL
isolated	NULL
MNC	NULL
or	NULL
day	NULL
7	NULL
effector	NULL
cells	NULL
were	NULL
analyzed	NULL
for	NULL
cell	NULL
surface	NULL
marker	NULL
expression	NULL
using	NULL
flow	NULL
cytometry	NULL
.	NULL

1.8	NULL
X	NULL
10°	NULL
cells	NULL
were	NULL
stimulated	NULL
in	NULL
CM	NULL
with	NULL
10	NULL
pg/ml	NULL
PHA	NULL
,	NULL
culture	NULL
supernatants	NULL
were	NULL
collected	NULL
after	NULL
24	NULL
h	NULL
,	NULL
and	NULL
cytokine	NULL
concentrations	NULL
were	NULL
measured	NULL
by	NULL
ELISA	NULL
;	NULL
values	NULL
shown	NULL
have	NULL
been	NULL
normalized	NULL
according	NULL
to	NULL
numbers	NULL
of	NULL
CD3*	NULL
cells	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

The	NULL
results	NULL
shown	NULL
are	NULL
derived	NULL
from	NULL
at	NULL
least	NULL
seven	NULL
indepen-	NULL
dent	NULL
experiments	NULL
.	NULL

*Non-CD3*	NULL
or	NULL
-CD19*	NULL
day	NULL
7	NULL
cells	NULL
expressed	NULL
monocyte	NULL
(	NULL
<	NULL
5	NULL
%	NULL
)	NULL
and	NULL
NK	NULL
cell	NULL
(	NULL
<	NULL
3	NULL
%	NULL
)	NULL
markers	NULL
.	NULL

1826	NULL
Inhibition	NULL
of	NULL
IFN-y	NULL
and	NULL
Stat1	NULL
by	NULL
Synovial	NULL
Fluids	NULL
Figure	NULL
1	NULL
.	NULL

-	NULL
Regulation	NULL
of	NULL
IFN-y	NULL
and	NULL
IL-4	NULL
secretion	NULL
by	NULL
SFs	NULL
and	NULL
cytokines	NULL
.	NULL

Priming	NULL
A	NULL
B	NULL
220	NULL
g	NULL
140	NULL
7	NULL
CJ	NULL
ieney	NULL
%	NULL
200	NULL
faa	NULL
<	NULL
3	NULL
T	NULL
120	NULL
-	NULL
T	NULL
&	NULL
&	NULL
z	NULL
z	NULL
#	NULL
100	NULL
-	NULL
7	NULL
6	NULL
2	NULL
g	NULL
6	NULL
Bo	NULL
-	NULL
2	NULL
p	NULL
5	NULL
£	NULL
#	NULL
c	NULL
§	NULL
se-	NULL
|I	NULL
)	NULL
|	NULL
©	NULL
40	NULL
4	NULL
P	NULL
Q	NULL
?	NULL

[	NULL
8	NULL
&	NULL
P	NULL
2	NULL
G	NULL
CZ	NULL
y	NULL
G2	NULL
$	NULL
»	NULL
-	NULL
|||	NULL
[	NULL
&	NULL
p	NULL
LM	NULL
Control	NULL
SFi	NULL
SF2	NULL
SFS	NULL
SF4	NULL
SFS	NULL
Control	NULL
TGF-8	NULL
IL40	NULL
PGE	NULL
IL12	NULL
cAMP	NULL
IL-12	NULL
.	NULL

-	NULL
IFNy	NULL
cultures	NULL
were	NULL
carried	NULL
out	NULL
(	NULL
4	NULL
)	NULL
in	NULL
CM	NULL
plus	NULL
30	NULL
%	NULL
plasma	NULL
(	NULL
control	NULL
)	NULL
or	NULL
30	NULL
%	NULL
FS	NULL
.	NULL

In	NULL
(	NULL
B	NULL
)	NULL
,	NULL
CM	NULL
was	NULL
supplemented	NULL
with	NULL
30	NULL
%	NULL
plasma	NULL
and	NULL
TGF-B	NULL
(	NULL
20	NULL
ng/m	NULL
!	NULL
)	NULL

IL-10	NULL
(	NULL
20	NULL
ng/	NULL
ml	NULL
)	NULL
,	NULL
PGE	NULL
,	NULL
(	NULL
107°	NULL
M	NULL
)	NULL
and	NULL
8-Br-cAMP	NULL
(	NULL
1	NULL
mM	NULL
)	NULL
,	NULL
IL-12	NULL
(	NULL
20	NULL
ng/ml	NULL
)	NULL
,	NULL
control	NULL
IgG	NULL
(	NULL
20	NULL
pg/ml	NULL
)	NULL
,	NULL
anti-IL-12	NULL
IgG	NULL
(	NULL
20	NULL
pg/ml	NULL
)	NULL
,	NULL
or	NULL
anti-IFN-y	NULL
IgG	NULL
(	NULL
20	NULL
pg/ml	NULL
)	NULL
.	NULL

On	NULL
day	NULL
7	NULL
,	NULL
cells	NULL
were	NULL
washed	NULL
and	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
;	NULL
1.8	NULL
X	NULL
105	NULL
effector	NULL
cells	NULL
,	NULL
containing	NULL
comparable	NULL
numbers	NULL
of	NULL
CD3+*	NULL
and	NULL
CD4*	NULL
cells	NULL
,	NULL
were	NULL
restimulated	NULL
in	NULL
CM	NULL
with	NULL
10	NULL
pg/ml	NULL
PHA	NULL
.	NULL

Culture	NULL
supernatants	NULL
were	NULL
harvested	NULL
after	NULL
24	NULL
h	NULL
,	NULL
and	NULL
cytokine	NULL
levels	NULL
were	NULL
assayed	NULL
by	NULL
ELISA	NULL
.	NULL

Cell	NULL
viability	NULL
(	NULL
>	NULL
90	NULL
%	NULL
)	NULL
and	NULL
cell	NULL
surface	NULL
phenotype	NULL
(	NULL
the	NULL
percentage	NULL
of	NULL
cells	NULL
that	NULL
were	NULL
CD3	NULL
#	NULL
,	NULL
CD4	NULL
,	NULL
CD8*	NULL
,	NULL
and	NULL
CD19+*	NULL
)	NULL
were	NULL
comparable	NULL
;	NULL
SFs	NULL
IgG	NULL
_	NULL
Anti-	NULL
_	NULL
Anti	NULL
decreased	NULL
cell	NULL
yield	NULL
by	NULL
20	NULL
%	NULL
.	NULL

Results	NULL
obtained	NULL
with	NULL
the	NULL
five	NULL
most	NULL
extensively	NULL
tested	NULL
SFs	NULL
are	NULL
shown	NULL
;	NULL
SFs	NULL
1	NULL
and	NULL
4	NULL
were	NULL
obtained	NULL
from	NULL
patients	NULL
seropositive	NULL
for	NULL
rheumatoid	NULL
factor	NULL
,	NULL
whereas	NULL
SFs	NULL
2	NULL
,	NULL
3	NULL
,	NULL
and	NULL
5	NULL
were	NULL
obtained	NULL
from	NULL
seronegative	NULL
patients	NULL
.	NULL

16	NULL
out	NULL
of	NULL
17	NULL
SFs	NULL
{	NULL
11	NULL
patients	NULL
seropositive	NULL
for	NULL
rheumatoid	NULL
factor	NULL
)	NULL
screened	NULL
inhibited	NULL
IFN-y	NULL
production	NULL
by	NULL
>	NULL
60	NULL
%	NULL
.	NULL

Data	NULL
are	NULL
shown	NULL
as	NULL
mean	NULL
relative	NULL
secretion	NULL
of	NULL
cytokines	NULL
+	NULL
SD	NULL
compared	NULL
with	NULL
the	NULL
control	NULL
culture	NULL
in	NULL
each	NULL
experiment	NULL
.	NULL

The	NULL
values	NULL
are	NULL
based	NULL
on	NULL
a	NULL
minimum	NULL
of	NULL
(	NULL
4	NULL
)	NULL
five	NULL
or	NULL
(	NULL
B	NULL
)	NULL
three	NULL
experiments	NULL
with	NULL
different	NULL
donors	NULL
.	NULL

more	NULL
IL-4	NULL
production	NULL
than	NULL
stimulation	NULL
of	NULL
freshly	NULL
isolated	NULL
cells	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
SFs	NULL
,	NULL
obtained	NULL
from	NULL
patients	NULL
with	NULL
active	NULL
inflammatory	NULL
arthritis	NULL
,	NULL
on	NULL
the	NULL
balance	NULL
of	NULL
cytokine	NULL
production	NULL
was	NULL
tested	NULL
next	NULL
.	NULL

Treatment	NULL
with	NULL
SFs	NULL
resulted	NULL
in	NULL
a	NULL
mean	NULL
81	NULL
%	NULL
inhibition	NULL
of	NULL
IFN-y	NULL
production	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
A	NULL
;	NULL
five	NULL
representative	NULL
SFs	NULL
out	NULL
of	NULL
17	NULL
tested	NULL
are	NULL
shown	NULL
)	NULL
and	NULL
a	NULL
parallel	NULL
inhibition	NULL
of	NULL
IFN-y	NULL
messenger	NULL
RNA	NULL
{	NULL
(	NULL
mRNA	NULL
)	NULL
levels	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
priming	NULL
for	NULL
IL-4	NULL
synthesis	NULL
was	NULL
largely	NULL
unaffected	NULL
,	NULL
because	NULL
SF-treated	NULL
cells	NULL
secreted	NULL
49-86	NULL
%	NULL
(	NULL
mean	NULL
74	NULL
%	NULL
)	NULL
as	NULL
much	NULL
IL-4	NULL
as	NULL
control	NULL
cells	NULL
.	NULL

Thus	NULL
,	NULL
treatment	NULL
with	NULL
SFs	NULL
resulted	NULL
in	NULL
the	NULL
preferential	NULL
inhibition	NULL
of	NULL
IFN-y	NULL
production	NULL
,	NULL
which	NULL
is	NULL
typical	NULL
of	NULL
a	NULL
Th2	NULL
response	NULL
.	NULL

Inflammatory	NULL
SFs	NULL
typically	NULL
contain	NULL
high	NULL
levels	NULL
of	NULL
factors	NULL
that	NULL
can	NULL
promote	NULL
Th2	NULL
responses	NULL
,	NULL
such	NULL
as	NULL
IL-10	NULL
,	NULL
PGEs	NULL
,	NULL
and	NULL
TGF-B	NULL
(	NULL
13	NULL
,	NULL
14	NULL
)	NULL
and	NULL
low	NULL
levels	NULL
of	NULL
IFN-y	NULL
(	NULL
15-17	NULL
)	NULL
;	NULL
many	NULL
contain	NULL
no	NULL
detectable	NULL
IL-12	NULL
(	NULL
Ivashkiv	NULL
,	NULL
L.-B	NULL
.	NULL

,	NULL
unpublished	NULL
data	NULL
)	NULL
.	NULL

Next	NULL
,	NULL
to	NULL
test	NULL
whether	NULL
any	NULL
of	NULL
these	NULL
agents	NULL
play	NULL
an	NULL
important	NULL
or	NULL
dominant	NULL
role	NULL
in	NULL
regulating	NULL
IFN-y	NULL
production	NULL
in	NULL
our	NULL
system	NULL
,	NULL
we	NULL
added	NULL
individual	NULL
agents	NULL
or	NULL
neutralizing	NULL
antibodies	NULL
to	NULL
the	NULL
priming	NULL
cultures	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
B	NULL
)	NULL
.	NULL

The	NULL
inhibitory	NULL
effect	NULL
of	NULL
SFs	NULL
on	NULL
IFN-y	NULL
production	NULL
was	NULL
mimicked	NULL
by	NULL
adding	NULL
IL-10	NULL
or	NULL
cAMP	NULL
,	NULL
or	NULL
by	NULL
neutralizing	NULL
either	NULL
IFN-y	NULL
or	NULL
IL-12	NULL
.	NULL

Thus	NULL
,	NULL
no	NULL
one	NULL
regulatory	NULL
factor	NULL
was	NULL
dominant	NULL
,	NULL
and	NULL
several	NULL
different	NULL
factors	NULL
or	NULL
mechanisms	NULL
could	NULL
mediate	NULL
the	NULL
SF	NULL
effect	NULL
.	NULL

Role	NULL
of	NULL
IL-4	NULL
,	NULL
IL-10	NULL
,	NULL
and	NULL
IL-12	NULL
in	NULL
Regulation	NULL
of	NULL
IFN-y	NULL
Production	NULL
by	NULL
SFs	NULL
.	NULL

_	NULL
SFs	NULL
contain	NULL
a	NULL
complex	NULL
mixture	NULL
of	NULL
cytokines	NULL
that	NULL
may	NULL
have	NULL
synergistic	NULL
or	NULL
antagonistic	NULL
effects	NULL
.	NULL

Furthermore	NULL
,	NULL
cytokines	NULL
detected	NULL
in	NULL
SFs	NULL
by	NULL
immunological	NULL
methods	NULL
may	NULL
be	NULL
denatured	NULL
or	NULL
complexed	NULL
to	NULL
inhibitors	NULL
and	NULL
have	NULL
no	NULL
bioactivity	NULL
(	NULL
16	NULL
,	NULL
19	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
rather	NULL
than	NULL
measuring	NULL
cytokine	NULL
levels	NULL
or	NULL
fractionating	NULL
SFs	NULL
to	NULL
attempt	NULL
to	NULL
identify	NULL
active	NULL
mol-ecules	NULL
,	NULL
we	NULL
used	NULL
neutralizing	NULL
antibodies	NULL
to	NULL
test	NULL
the	NULL
effect	NULL
of	NULL
blocking	NULL
cytokine	NULL
activity	NULL
during	NULL
the	NULL
priming	NULL
period	NULL
.	NULL

Neutralization	NULL
of	NULL
both	NULL
IL-10	NULL
and	NULL
IL-4	NULL
during	NULL
priming	NULL
was	NULL
required	NULL
to	NULL
reverse	NULL
the	NULL
SF	NULL
inhibition	NULL
of	NULL
IFN-y	NULL
production	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
A	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
(	NULL
7	NULL
)	NULL
,	NULL
priming	NULL
for	NULL
IL-4	NULL
production	NULL
in	NULL
1827	NULL
Wang	NULL
et	NULL
al	NULL
.	NULL

both	NULL
control	NULL
and	NULL
SF-treated	NULL
cultures	NULL
depended	NULL
on	NULL
the	NULL
presence	NULL
of	NULL
IL-4	NULL
during	NULL
the	NULL
priming	NULL
period	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
B	NULL
)	NULL
.	NULL

IL-10	NULL
is	NULL
expressed	NULL
in	NULL
inflamed	NULL
synovium	NULL
(	NULL
14	NULL
)	NULL
and	NULL
inhibits	NULL
production	NULL
of	NULL
several	NULL
accessory	NULL
cell-derived	NULL
cytokines	NULL
,	NULL
including	NULL
the	NULL
Th1	NULL
stimulatory	NULL
cytokine	NULL
IL-12	NULL
(	NULL
20	NULL
)	NULL
.	NULL

We	NULL
investigated	NULL
whether	NULL
SF	NULL
treatment	NULL
resulted	NULL
in	NULL
a	NULL
deficit	NULL
in	NULL
en-dogenous	NULL
IL-12	NULL
activity	NULL
in	NULL
priming	NULL
cultures	NULL
.	NULL

SFs	NULL
specifically	NULL
suppressed	NULL
induction	NULL
of	NULL
IL-12	NULL
mRNA	NULL
during	NULL
initiation	NULL
of	NULL
priming	NULL
cultures	NULL
,	NULL
because	NULL
treatment	NULL
with	NULL
SFs	NULL
resulted	NULL
in	NULL
significantly	NULL
lower	NULL
levels	NULL
of	NULL
IL-12	NULL
but	NULL
not	NULL
IL-2	NULL
mRNA	NULL
3	NULL
h	NULL
after	NULL
stimulation	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Addition	NULL
of	NULL
exogenous	NULL
IL-12	NULL
to	NULL
control	NULL
cultures	NULL
resulted	NULL
in	NULL
a	NULL
modest	NULL
stimulation	NULL
of	NULL
IFN-y	NULL
production	NULL
(	NULL
Figs	NULL
.	NULL

1	NULL
B	NULL
and	NULL
2	NULL
A	NULL
)	NULL
,	NULL
probably	NULL
because	NULL
endoge-nously	NULL
produced	NULL
IL-12	NULL
is	NULL
present	NULL
at	NULL
near	NULL
saturating	NULL
levels	NULL
in	NULL
our	NULL
culture	NULL
system	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
addition	NULL
of	NULL
exogenous	NULL
IL-12	NULL
to	NULL
SF-treated	NULL
cultures	NULL
resulted	NULL
in	NULL
a	NULL
dramatic	NULL
ninefold	NULL
induction	NULL
of	NULL
IFN-y	NULL
production	NULL
and	NULL
a	NULL
reversal	NULL
of	NULL
SF	NULL
inhibition	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
C	NULL
and	NULL
D	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
results	NULL
show	NULL
that	NULL
SF	NULL
treatment	NULL
resulted	NULL
in	NULL
a	NULL
relative	NULL
deficit	NULL
in	NULL
IL-12	NULL
ac-tivity	NULL
.	NULL

Our	NULL
results	NULL
demonstrate	NULL
that	NULL
SFs	NULL
regulated	NULL
priming	NULL
by	NULL
modulating	NULL
expression	NULL
of	NULL
several	NULL
regulatory	NULL
cytokines	NULL
during	NULL
the	NULL
priming	NULL
period	NULL
.	NULL

Parallel	NULL
Regulation	NULL
of	NULL
Stat1	NULL
Activity	NULL
and	NULL
Priming	NULL
for	NULL
IFN-y	NULL
Production	NULL
.	NULL

-	NULL
Because	NULL
many	NULL
of	NULL
the	NULL
cytokines	NULL
that	NULL
regulate	NULL
T	NULL
cell	NULL
differentiation	NULL
activate	NULL
STAT	NULL
's	NULL
,	NULL
we	NULL
investigated	NULL
the	NULL
activation	NULL
of	NULL
STAT	NULL
DNA	NULL
binding	NULL
activity	NULL
during	NULL
priming	NULL
cultures	NULL
by	NULL
using	NULL
gel	NULL
shift	NULL
assays	NULL
.	NULL

Binding	NULL
of	NULL
three	NULL
complexes	NULL
of	NULL
similar	NULL
mobility	NULL
to	NULL
the	NULL
hSIE	NULL
oligonucleotide	NULL
(	NULL
18	NULL
)	NULL
was	NULL
induced	NULL
in	NULL
control	NULL
cultures	NULL
,	NULL
where	NULL
priming	NULL
for	NULL
both	NULL
IFN-y	NULL
and	NULL
IL-4	NULL
production	NULL
occurs	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
A	NULL
,	NULL
lane	NULL
4	NULL
,	NULL
and	NULL
C	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

DNA	NULL
binding	NULL
was	NULL
specific	NULL
for	NULL
the	NULL
STAT	NULL
sequence	NULL
within	NULL
the	NULL
hSIE	NULL
,	NULL
derived	NULL
predominantly	NULL
from	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
was	NULL
dependent	NULL
on	NULL
tyrosine	NULL
phosphorylation	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

STAT	NULL
DNA	NULL
binding	NULL
activity	NULL
was	NULL
not	NULL
detected	NULL
until	NULL
~1	NULL
d	NULL
after	NULL
stimulation	NULL
;	NULL
it	NULL
peaked	NULL
at	NULL
1-2	NULL
d	NULL
and	NULL
persisted	NULL
over	NULL
at	NULL
least	NULL
3	NULL
d	NULL
of	NULL
priming	NULL
culture	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
4	NULL
,	NULL
lanes	NULL
C	NULL
]	NULL
e	NULL
Anti-10	NULL
Antica	NULL
[	NULL
BB	NULL
]	NULL
anettasanti-10	NULL
Relative	NULL
Secretion	NULL
of	NULL
IFN-y	NULL
3	NULL
I	NULL
Relative	NULL
Secretion	NULL
of	NULL
IL-4	NULL
3	NULL
6	NULL
1	NULL
BOY	NULL
antics	NULL
[	NULL
B	NULL
)	NULL
Ant	NULL
to	NULL
20	NULL
-	NULL
A	NULL
P	NULL
20	NULL
-	NULL
_	NULL
f	NULL
0	NULL
-	NULL
7A	NULL
|2§	NULL
A	NULL
0	NULL
-	NULL
é4§	NULL
Z§	NULL
Control	NULL
sra	NULL
SFs	NULL
Control	NULL
Sre	NULL
SFS	NULL
C	NULL
D	NULL
250	NULL
120	NULL
AlL-12	NULL
100	NULL
-	NULL
H	NULL
)	NULL
r	NULL
>	NULL
Figure	NULL
2	NULL
.	NULL

-	NULL
Role	NULL
of	NULL
IL-4	NULL
,	NULL
IL-10	NULL
,	NULL
and	NULL
IL-12	NULL
&	NULL
.	NULL

200	NULL
-	NULL
3	NULL
in	NULL
regulation	NULL
of	NULL
cytokine	NULL
secretion	NULL
by	NULL
SFs	NULL
.	NULL

E	NULL
g	NULL
=	NULL
!	NULL

(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
Cells	NULL
were	NULL
primed	NULL
and	NULL
cultured	NULL
*S	NULL
150	NULL
-	NULL
Z	NULL
E	NULL
80	NULL
-	NULL
w	NULL
with	NULL
SFs	NULL
and	NULL
neutralizing	NULL
IgG	NULL
to	NULL
IL-10	NULL
5	NULL
g	NULL
5	NULL
g	NULL
(	NULL
20	NULL
g/m	NULL
!	NULL
)	NULL

or	NULL
IL-4	NULL
(	NULL
20	NULL
jig/ml	NULL
)	NULL
.	NULL

Control	NULL
T	NULL
g	NULL
$	NULL
60	NULL
-	NULL
é	NULL
IgG	NULL
was	NULL
used	NULL
to	NULL
achieve	NULL
a	NULL
total	NULL
IgG	NULL
cong	NULL
100	NULL
-	NULL
Z	NULL
Fa	NULL
g	NULL
centration	NULL
of	NULL
40	NULL
pg/ml	NULL
!	NULL

in	NULL
each	NULL
culture	NULL
.	NULL

o	NULL
g	NULL
®	NULL
49	NULL
-	NULL
Z	NULL
Results	NULL
obtained	NULL
with	NULL
two	NULL
representative	NULL
hi	NULL
é	NULL
I	NULL
%	NULL
SFs	NULL
are	NULL
shown	NULL
.	NULL

(	NULL
C	NULL
and	NULL
D	NULL
)	NULL
IL-12	NULL
(	NULL
20	NULL
ng/	NULL
E	NULL
50	NULL
-	NULL
g	NULL
C	NULL
é	NULL
ml	NULL
)	NULL
was	NULL
added	NULL
at	NULL
initiation	NULL
of	NULL
cultures	NULL
.	NULL

Cell	NULL
Z	NULL
20	NULL
-	NULL
g	NULL
surface	NULL
phenotype	NULL
,	NULL
viability	NULL
,	NULL
and	NULL
yield	NULL
were	NULL
%	NULL
g	NULL
comparable	NULL
in	NULL
all	NULL
cultures	NULL
.	NULL

The	NULL
values	NULL
for	NULL
0	NULL
-	NULL
11	NULL
0	NULL
-	NULL
L	NULL
relative	NULL
cytokine	NULL
secretion	NULL
are	NULL
based	NULL
on	NULL
Control	NULL
SF1	NULL
-	NULL
SF2	NULL
-	NULL
SF3	NULL
-	NULL
sF4	NULL
-	NULL
SFS	NULL
Control	NULL
|	NULL
sFa	NULL
SF4	NULL
-	NULL
srs	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

1-4	NULL
,	NULL
and	NULL
C	NULL
,	NULL
lanes	NULL
1-4	NULL
)	NULL
.	NULL

This	NULL
result	NULL
contrasts	NULL
with	NULL
the	NULL
previously	NULL
described	NULL
rapid	NULL
activation	NULL
of	NULL
STAT	NULL
's	NULL
after	NULL
treatment	NULL
with	NULL
high	NULL
concentrations	NULL
of	NULL
purified	NULL
cytokines	NULL
(	NULL
8	NULL
,	NULL
9	NULL
)	NULL
,	NULL
which	NULL
we	NULL
could	NULL
reproduce	NULL
in	NULL
our	NULL
system	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
A	NULL
,	NULL
lanes	NULL
5-7	NULL
)	NULL
.	NULL

The	NULL
most	NULL
straightforward	NULL
interpretation	NULL
of	NULL
these	NULL
data	NULL
is	NULL
that	NULL
the	NULL
initial	NULL
priming	NULL
stimulation	NULL
with	NULL
PHA	NULL
does	NULL
not	NULL
activate	NULL
%	NULL
cDNA	NULL
:	NULL
5	NULL
1	NULL
§	NULL
1	NULL
51	NULL
51	NULL
5	NULL
1	NULL
51	NULL
IL-2	NULL
»	NULL
w	NULL
»	NULL
-	NULL
w	NULL
»	NULL
w	NULL
»	NULL
IL-12-	NULL
»	NULL
==	NULL
GAPDH	NULL
--	NULL
«	NULL
-	NULL
<	NULL
-	NULL
<	NULL
&	NULL
<	NULL
-	NULL
L_JL_IJL_JL__JL__IL_J	NULL
CTL	NULL
SF3	NULL
SF4	NULL
,	NULL
CTL	NULL
SF3	NULL
SF4	NULL
-	NULL
PHA	NULL
+	NULL
PHA	NULL
Figure	NULL
3	NULL
.	NULL

-	NULL
Regulation	NULL
of	NULL
IL-2	NULL
and	NULL
IL-12	NULL
mRNA	NULL
levels	NULL
by	NULL
SFs	NULL
.	NULL

Peripheral	NULL
blood	NULL
MNCs	NULL
were	NULL
stimulated	NULL
with	NULL
1.3	NULL
ug/ml	NULL
PHA	NULL
,	NULL
and	NULL
cells	NULL
were	NULL
harvested	NULL
after	NULL
3	NULL
h	NULL
,	NULL
RNA	NULL
extracted	NULL
,	NULL
and	NULL
reverse	NULL
transcribed	NULL
into	NULL
cDNA	NULL
.	NULL

IL-2	NULL
,	NULL
IL-12	NULL
p40	NULL
subunit	NULL
,	NULL
and	NULL
mRNA	NULL
levels	NULL
were	NULL
compared	NULL
using	NULL
semi-quantitative	NULL
PCR	NULL
,	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

For	NULL
each	NULL
sam-ple	NULL
,	NULL
two	NULL
different	NULL
quantities	NULL
of	NULL
cDNA	NULL
(	NULL
5	NULL
and	NULL
1	NULL
%	NULL
of	NULL
cDNA	NULL
obtained	NULL
using	NULL
1	NULL
ug	NULL
of	NULL
RNA	NULL
)	NULL
were	NULL
subjected	NULL
to	NULL
PCR	NULL
.	NULL

1828	NULL
STAT	NULL
's	NULL
,	NULL
but	NULL
subsequent	NULL
production	NULL
of	NULL
cytokines	NULL
during	NULL
culture	NULL
results	NULL
in	NULL
a	NULL
delayed	NULL
activation	NULL
.	NULL

The	NULL
hSIE	NULL
oligonucleotide	NULL
used	NULL
in	NULL
our	NULL
studies	NULL
preferentially	NULL
binds	NULL
protein	NULL
complexes	NULL
that	NULL
contain	NULL
Stat1	NULL
and	NULL
Stat3	NULL
,	NULL
termed	NULL
serum-inducible	NULL
factor	NULL
(	NULL
SIF	NULL
)	NULL
A	NULL
(	NULL
upper	NULL
complex	NULL
,	NULL
which	NULL
contains	NULL
Stat3	NULL
)	NULL
,	NULL
SIF-B	NULL
{	NULL
middle	NULL
complex	NULL
,	NULL
which	NULL
contains	NULL
both	NULL
Stat3	NULL
and	NULL
Stat1	NULL
)	NULL
,	NULL
and	NULL
SIF-C	NULL
(	NULL
lower	NULL
complex	NULL
,	NULL
which	NULL
is	NULL
a	NULL
homodimer	NULL
of	NULL
Stat1	NULL
)	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Because	NULL
the	NULL
STAT	NULL
complexes	NULL
induced	NULL
during	NULL
priming	NULL
had	NULL
an	NULL
identical	NULL
mobility	NULL
to	NULL
SIF-A	NULL
,	NULL
-B	NULL
,	NULL
and	NULL
-C	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
we	NULL
tested	NULL
whether	NULL
these	NULL
complexes	NULL
reacted	NULL
with	NULL
specific	NULL
antisera	NULL
against	NULL
Stat	NULL
!	NULL

or	NULL
Stat3	NULL
(	NULL
18	NULL
)	NULL
in	NULL
supershift	NULL
experiments	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
B	NULL
)	NULL
.	NULL

The	NULL
lower	NULL
two	NULL
complexes	NULL
reacted	NULL
with	NULL
the	NULL
Stat1	NULL
antiserum	NULL
,	NULL
whereas	NULL
the	NULL
upper	NULL
two	NULL
complexes	NULL
reacted	NULL
with	NULL
the	NULL
Stat3	NULL
antiserum	NULL
.	NULL

Thus	NULL
,	NULL
priming	NULL
resulted	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
Statl	NULL
and	NULL
Stat3	NULL
,	NULL
and	NULL
the	NULL
complexes	NULL
we	NULL
have	NULL
detected	NULL
probably	NULL
correspond	NULL
to	NULL
SIF-A	NULL
,	NULL
-B	NULL
,	NULL
and	NULL
-C.	NULL
Interestingly	NULL
,	NULL
treatment	NULL
with	NULL
SFs	NULL
,	NULL
which	NULL
suppressed	NULL
priming	NULL
for	NULL
IFN-y	NULL
but	NULL
not	NULL
IL-4	NULL
production	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
A	NULL
)	NULL
,	NULL
resulted	NULL
in	NULL
the	NULL
preferential	NULL
suppression	NULL
of	NULL
the	NULL
lower	NULL
two	NULL
complexes	NULL
,	NULL
which	NULL
contain	NULL
Stat1	NULL
,	NULL
throughout	NULL
the	NULL
time	NULL
course	NULL
of	NULL
the	NULL
experiment	NULL
(	NULL
Figs	NULL
.	NULL

4	NULL
C	NULL
and	NULL
5	NULL
A	NULL
)	NULL
.	NULL

The	NULL
inhibition	NULL
of	NULL
Stat1l	NULL
activity	NULL
was	NULL
not	NULL
secondary	NULL
to	NULL
down-regulation	NULL
of	NULL
Stat1	NULL
protein	NULL
levels	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
and	NULL
thus	NULL
reflected	NULL
regulation	NULL
of	NULL
DNA	NULL
binding	NULL
.	NULL

We	NULL
next	NULL
investigated	NULL
the	NULL
relationship	NULL
between	NULL
successful	NULL
priming	NULL
for	NULL
IFN-y	NULL
production	NULL
and	NULL
the	NULL
activity	NULL
of	NULL
Statl	NULL
Inhibition	NULL
of	NULL
IFN-y	NULL
and	NULL
Stat1	NULL
by	NULL
Synovial	NULL
Fluids	NULL
w	NULL
SIF-A/Stat	NULL
SIF-C/Stat	NULL
1-	NULL
»	NULL
-1	NULL
2	NULL
3	NULL
C	NULL
PHA	NULL
:	NULL
-	NULL
+	NULL
tot	NULL
+	NULL
+	NULL
-	NULL
=	NULL
=	NULL
+	NULL
#	NULL
+	NULL
#	NULL
Time	NULL
(	NULL
d	NULL
)	NULL
:	NULL
0	NULL
1	NULL
2	NULL
4	NULL
1	NULL
2	NULL
4	NULL
sm-s	NULL
[	NULL
“	NULL
w	NULL
“	NULL
.ﬂ	NULL
”	NULL
Sp1	NULL
-	NULL
»	NULL
10	NULL
2	NULL
s	NULL
4	NULL
§	NULL
06	NULL
7	NULL
Figure	NULL
4	NULL
.	NULL

-	NULL
Regulation	NULL
of	NULL
STAT	NULL
DNA	NULL
binding	NULL
activity	NULL
during	NULL
priming	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
at	NULL
the	NULL
indicated	NULL
time	NULL
points	NULL
,	NULL
and	NULL
8	NULL
jug	NULL
of	NULL
cell	NULL
extract	NULL
was	NULL
assayed	NULL
for	NULL
binding	NULL
to	NULL
a	NULL
radiolabeled	NULL
hSIE	NULL
oligonucleotide	NULL
(	NULL
containing	NULL
a	NULL
STAT	NULL
binding	NULL
site	NULL
;	NULL
reference	NULL
18	NULL
)	NULL
or	NULL
to	NULL
a	NULL
control	NULL
Spi	NULL
oligonucleotide	NULL
using	NULL
gel	NULL
shift	NULL
assays	NULL
.	NULL

Representative	NULL
experiments	NULL
are	NULL
shown	NULL
.	NULL

(	NULL
4	NULL
)	NULL
IFN-y	NULL
(	NULL
100	NULL
U/zmi	NULL
)	NULL
was	NULL
added	NULL
in	NULL
lanes	NULL
5-7	NULL
.	NULL

(	NULL
B	NULL
)	NULL
1	NULL
pul	NULL
of	NULL
a	NULL
1:10	NULL
dilution	NULL
of	NULL
specific	NULL
anti-Stat1	NULL
or	NULL
anti-Stat3	NULL
antiserum	NULL
(	NULL
18	NULL
)	NULL
was	NULL
incubated	NULL
with	NULL
extracts	NULL
(	NULL
ob-tained	NULL
24	NULL
h	NULL
after	NULL
PHA	NULL
stimulation	NULL
)	NULL
for	NULL
15	NULL
min	NULL
before	NULL
adding	NULL
radiolabeled	NULL
probe	NULL
.	NULL

(	NULL
C	NULL
)	NULL
SF	NULL
was	NULL
used	NULL
at	NULL
30	NULL
%	NULL
final	NULL
concentration	NULL
.	NULL

during	NULL
the	NULL
priming	NULL
period	NULL
.	NULL

IL-12	NULL
,	NULL
IFN-y	NULL
,	NULL
and	NULL
antibodies	NULL
to	NULL
IL-4	NULL
and	NULL
IL-10	NULL
,	NULL
which	NULL
blocked	NULL
SF	NULL
inhibition	NULL
of	NULL
IFN-y	NULL
production	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
also	NULL
blocked	NULL
SF	NULL
inhibition	NULL
of	NULL
Stat1	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
A	NULL
,	NULL
lanes	NULL
1-12	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
treatments	NULL
that	NULL
mimicked	NULL
SF	NULL
inhibition	NULL
of	NULL
IFN-y	NULL
production	NULL
,	NULL
such	NULL
as	NULL
neutralization	NULL
of	NULL
IFN-y	NULL
or	NULL
IL-12	NULL
,	NULL
or	NULL
addition	NULL
of	NULL
cAMP	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
B	NULL
)	NULL
,	NULL
also	NULL
inhibited	NULL
Statl	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
A	NULL
,	NULL
lanes	NULL
13-15	NULL
)	NULL
but	NULL
did	NULL
not	NULL
affect	NULL
Stat1	NULL
protein	NULL
levels	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
several	NULL
factors	NULL
differentially	NULL
regulated	NULL
the	NULL
delayed	NULL
phase	NULL
of	NULL
Stat1	NULL
activity	NULL
in	NULL
parallel	NULL
with	NULL
the	NULL
differential	NULL
regulation	NULL
of	NULL
Th1	NULL
and	NULL
Th2	NULL
responses	NULL
.	NULL

Patten	NULL
of	NULL
STAT	NULL
Activity	NULL
during	NULL
Synovitis	NULL
.	NULL

We	NULL
investigated	NULL
whether	NULL
the	NULL
pattern	NULL
of	NULL
STAT	NULL
DNA	NULL
binding	NULL
activity	NULL
detected	NULL
in	NULL
SF-treated	NULL
cultures	NULL
reflected	NULL
the	NULL
pattern	NULL
of	NULL
STAT	NULL
activity	NULL
in	NULL
vivo	NULL
during	NULL
synovial	NULL
inflammation	NULL
.	NULL

Extracts	NULL
prepared	NULL
from	NULL
cells	NULL
freshly	NULL
isolated	NULL
from	NULL
joint	NULL
effusions	NULL
of	NULL
patients	NULL
with	NULL
inflammatory	NULL
arthritis	NULL
contained	NULL
predominantly	NULL
Stat3	NULL
but	NULL
not	NULL
Stat1l	NULL
DNA	NULL
binding	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
B	NULL
)	NULL
.	NULL

This	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
inability	NULL
of	NULL
several	NULL
groups	NULL
,	NULL
including	NULL
ours	NULL
,	NULL
to	NULL
detect	NULL
IFN-y	NULL
protein	NULL
in	NULL
inflammatory	NULL
arthritis	NULL
(	NULL
15-17	NULL
)	NULL
.	NULL

1829	NULL
Wang	NULL
et	NULL
al	NULL
.	NULL

A	NULL
s	NULL
&	NULL
5ox	NULL
>	NULL
o	NULL
>	NULL
w	NULL
«	NULL
3	NULL
3	NULL
w	NULL
2	NULL
2	NULL
1	NULL
t	NULL
5	NULL
&	NULL
G	NULL
ko	NULL
&	NULL
<	NULL
2	NULL
=S	NULL
8	NULL
8	NULL
_	NULL
&	NULL
++++++735§	NULL
--	NULL
Wo	NULL
®	NULL
so	NULL
180	NULL
m	NULL
©	NULL
@	NULL
x	NULL
m	NULL
abou	NULL
ll	NULL
.	NULL

Lo	NULL
k	NULL
&	NULL
&	NULL
iE	NULL
ok	NULL
&	NULL
oO	NULL
Rouk	NULL
L	NULL
&	NULL
=	NULL
T	NULL
d	NULL
do	NULL
56	NULL
a	NULL
#	NULL
b	NULL
h	NULL
t	NULL
4	NULL
5	NULL
i	NULL
o	NULL
s	NULL
s	NULL
§	NULL
+o	NULL
t	NULL
+	NULL
+0	NULL
+	NULL
to	NULL
ko	NULL
4	NULL
4	NULL
#	NULL
+	NULL
4	NULL
4	NULL
+	NULL
up	NULL
u	NULL
5	NULL
ad	NULL
hta	NULL
y	NULL
+	NULL
1020	NULL
3	NULL
4	NULL
50	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
i112	NULL
13	NULL
14	NULL
15	NULL
B	NULL
monocytes	NULL
_	NULL
synovial	NULL
+	NULL
IFNy	NULL
cells	NULL
=	NULL
%	NULL
zo	NULL
9	NULL
s	NULL
8	NULL
Ss	NULL
-	NULL
3	NULL
3	NULL
._	NULL
0	NULL
®	NULL
Lo	NULL
&	NULL
s	NULL
L	NULL
&	NULL
s	NULL
w	NULL
#	NULL
Pile	NULL
,	NULL
``	NULL
*	NULL
Stat	NULL
1	NULL
-	NULL
»	NULL
u	NULL
MN	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
Figure	NULL
5	NULL
.	NULL

Modulation	NULL
of	NULL
STAT	NULL
DNA	NULL
binding	NULL
activity	NULL
by	NULL
SFs	NULL
and	NULL
inflammatory	NULL
stimuli	NULL
.	NULL

(	NULL
4	NULL
)	NULL
Extracts	NULL
from	NULL
cells	NULL
primed	NULL
for	NULL
2	NULL
d	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
indicated	NULL
stimuli	NULL
were	NULL
assayed	NULL
for	NULL
binding	NULL
to	NULL
a	NULL
radiolabeled	NULL
hSIE	NULL
oligonucleotide	NULL
(	NULL
18	NULL
)	NULL
.	NULL

The	NULL
SFs	NULL
,	NULL
cytokines	NULL
,	NULL
and	NULL
neutralizing	NULL
antibodies	NULL
were	NULL
used	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legends	NULL
to	NULL
Figs	NULL
.	NULL

1	NULL
and	NULL
2	NULL
.	NULL

(	NULL
B	NULL
)	NULL
hSIE	NULL
binding	NULL
by	NULL
control	NULL
extracts	NULL
from	NULL
IFN-y-stimulated	NULL
monocytes	NULL
(	NULL
which	NULL
contain	NULL
Stat1	NULL
;	NULL
reference	NULL
17	NULL
)	NULL
was	NULL
compared	NULL
with	NULL
binding	NULL
by	NULL
extracts	NULL
from	NULL
synovial	NULL
cells	NULL
freshly	NULL
isolated	NULL
from	NULL
inflamed	NULL
joint	NULL
effusions	NULL
.	NULL

A	NULL
representative	NULL
extract	NULL
from	NULL
the	NULL
six	NULL
extracts	NULL
tested	NULL
is	NULL
shown	NULL
.	NULL

1	NULL
wl	NULL
of	NULL
a	NULL
1:10	NULL
dilution	NULL
of	NULL
each	NULL
specific	NULL
antiserum	NULL
(	NULL
18	NULL
)	NULL
was	NULL
used	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
in	NULL
delayed-type	NULL
hypersensitivity	NULL
,	NULL
a	NULL
Th1	NULL
response	NULL
,	NULL
active	NULL
Stat1	NULL
is	NULL
present	NULL
in	NULL
skin	NULL
lesions	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Discussion	NULL
Relatively	NULL
little	NULL
is	NULL
known	NULL
about	NULL
the	NULL
mechanisms	NULL
that	NULL
regulate	NULL
the	NULL
balance	NULL
of	NULL
Th1	NULL
versus	NULL
Th2	NULL
cytokine	NULL
production	NULL
during	NULL
chronic	NULL
human	NULL
inflammatory	NULL
diseases	NULL
such	NULL
as	NULL
synovitis	NULL
.	NULL

T	NULL
cells	NULL
that	NULL
enter	NULL
inflamed	NULL
synovium	NULL
are	NULL
exposed	NULL
to	NULL
multiple	NULL
agonists	NULL
and	NULL
antagonists	NULL
that	NULL
preexist	NULL
in	NULL
the	NULL
joint	NULL
or	NULL
are	NULL
produced	NULL
by	NULL
cells	NULL
as	NULL
they	NULL
become	NULL
activated	NULL
.	NULL

We	NULL
have	NULL
investigated	NULL
mechanisms	NULL
regulating	NULL
cytokine	NULL
production	NULL
using	NULL
a	NULL
culture	NULL
system	NULL
that	NULL
attempts	NULL
to	NULL
mimic	NULL
the	NULL
complexity	NULL
of	NULL
regulation	NULL
in	NULL
vivo	NULL
.	NULL

Our	NULL
results	NULL
show	NULL
that	NULL
soluble	NULL
synovial	NULL
inflammatory	NULL
mediators	NULL
specifically	NULL
inhibit	NULL
transcription	NULL
factor	NULL
Stat1	NULL
in	NULL
PHA-activated	NULL
T	NULL
cells	NULL
.	NULL

A	NULL
functional	NULL
correlate	NULL
of	NULL
Stat1	NULL
suppression	NULL
is	NULL
the	NULL
inhibition	NULL
of	NULL
development	NULL
of	NULL
effector	NULL
T	NULL
cells	NULL
that	NULL
produce	NULL
high	NULL
levels	NULL
of	NULL
IFN-y	NULL
.	NULL

Stat	NULL
!	NULL

activity	NULL
and	NULL
IFN-y	NULL
production	NULL
were	NULL
regulated	NULL
in	NULL
parallel	NULL
by	NULL
a	NULL
cytokine	NULL
regulatory	NULL
network	NULL
that	NULL
involved	NULL
IL-4	NULL
,	NULL
IL-10	NULL
,	NULL
and	NULL
IL-12	NULL
and	NULL
was	NULL
modulated	NULL
by	NULL
SFs	NULL
.	NULL

IL-4	NULL
,	NULL
IL-10	NULL
,	NULL
and	NULL
IL-12	NULL
have	NULL
previously	NULL
been	NULL
shown	NULL
to	NULL
regulate	NULL
Th1	NULL
versus	NULL
Th2	NULL
cytokine	NULL
production	NULL
(	NULL
7	NULL
)	NULL
.	NULL

In	NULL
many	NULL
systems	NULL
,	NULL
IL-4	NULL
alone	NULL
is	NULL
sufficient	NULL
to	NULL
induce	NULL
a	NULL
Th2	NULL
response	NULL
and	NULL
is	NULL
dominant	NULL
over	NULL
IL-12	NULL
(	NULL
7	NULL
,	NULL
22	NULL
)	NULL
.	NULL

SF	NULL
suppression	NULL
of	NULL
IFN-y	NULL
production	NULL
required	NULL
IL-10	NULL
(	NULL
and	NULL
inhibition	NULL
of	NULL
IL-12	NULL
)	NULL
in	NULL
ad	NULL
dition	NULL
to	NULL
IL-4	NULL
,	NULL
and	NULL
exogenous	NULL
IL-12	NULL
restored	NULL
IFN-y	NULL
production	NULL
in	NULL
a	NULL
dominant	NULL
fashion	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
accessory	NULL
cell-derived	NULL
factors	NULL
,	NULL
such	NULL
as	NULL
IL-10	NULL
and	NULL
IL-12	NULL
,	NULL
may	NULL
play	NULL
an	NULL
important	NULL
or	NULL
dominant	NULL
role	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
T	NULL
cell	NULL
cytokine	NULL
production	NULL
during	NULL
synovial	NULL
inflammation	NULL
.	NULL

The	NULL
imbalance	NULL
in	NULL
cytokine	NULL
production	NULL
we	NULL
have	NULL
described	NULL
reflects	NULL
the	NULL
pattern	NULL
of	NULL
cytokine	NULL
expression	NULL
in	NULL
chronic	NULL
human	NULL
synovitis	NULL
and	NULL
CAEV	NULL
-associated	NULL
arthritis	NULL
(	NULL
6	NULL
,	NULL
13	NULL
)	NULL
.	NULL

Th2	NULL
cytokines	NULL
can	NULL
contribute	NULL
to	NULL
pathogenesis	NULL
by	NULL
driving	NULL
synovial	NULL
production	NULL
of	NULL
antibodies	NULL
and	NULL
formation	NULL
of	NULL
immune	NULL
complexes	NULL
,	NULL
or	NULL
by	NULL
inducing	NULL
expression	NULL
of	NULL
metalloproteases	NULL
(	NULL
23	NULL
)	NULL
and	NULL
inflammatory	NULL
mediators	NULL
,	NULL
such	NULL
as	NULL
soluble	NULL
CD23	NULL
(	NULL
24	NULL
)	NULL
.	NULL

Alternatively	NULL
,	NULL
Th2	NULL
cytokines	NULL
may	NULL
contribute	NULL
to	NULL
pathogenesis	NULL
by	NULL
suppressing	NULL
Th1-mediated	NULL
clearance	NULL
of	NULL
(	NULL
auto	NULL
)	NULL
antigens	NULL
or	NULL
inappropriately	NULL
activated	NULL
cells	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Statl	NULL
activity	NULL
in	NULL
priming	NULL
cultures	NULL
was	NULL
differentially	NULL
regulated	NULL
by	NULL
SFs	NULL
,	NULL
cAMP	NULL
,	NULL
IL-4	NULL
,	NULL
IFN-y	NULL
,	NULL
and	NULL
IL-12	NULL
(	NULL
Figs	NULL
.	NULL

4	NULL
and	NULL
5	NULL
;	NULL
Wang	NULL
,	NULL
F.	NULL
,	NULL
unpublished	NULL
data	NULL
)	NULL
.	NULL

This	NULL
antagonistic	NULL
regulation	NULL
of	NULL
a	NULL
STAT	NULL
factor	NULL
by	NULL
several	NULL
opposing	NULL
cytokines	NULL
represents	NULL
a	NULL
novel	NULL
mechanism	NULL
for	NULL
modulating	NULL
STAT	NULL
signaling	NULL
and	NULL
allows	NULL
Stat1	NULL
to	NULL
function	NULL
as	NULL
a	NULL
cellular	NULL
``	NULL
node	NULL
``	NULL
that	NULL
integrates	NULL
multiple	NULL
signals	NULL
into	NULL
a	NULL
transcriptional	NULL
response	NULL
.	NULL

The	NULL
block	NULL
of	NULL
Stat1	NULL
activity	NULL
could	NULL
be	NULL
achieved	NULL
by	NULL
preventing	NULL
production	NULL
of	NULL
the	NULL
cytokine	NULL
,	NULL
which	NULL
directly	NULL
activates	NULL
Stat1	NULL
,	NULL
interruption	NULL
of	NULL
intracellular	NULL
signals	NULL
upstream	NULL
of	NULL
Stat1	NULL
activation	NULL
(	NULL
12	NULL
)	NULL
or	NULL
activation	NULL
of	NULL
Stat1-specific	NULL
tyrosine	NULL
phosphatases	NULL
.	NULL

At	NULL
this	NULL
time	NULL
,	NULL
it	NULL
is	NULL
not	NULL
clear	NULL
which	NULL
cytokine	NULL
directly	NULL
activates	NULL
Statl	NULL
in	NULL
priming	NULL
cultures	NULL
.	NULL

Stat1l	NULL
can	NULL
be	NULL
activated	NULL
by	NULL
many	NULL
cytokines	NULL
,	NULL
including	NULL
IFN-y	NULL
,	NULL
IFN-	NULL
,	NULL
IL-2	NULL
,	NULL
IL-6	NULL
,	NULL
platelet-derived	NULL
growth	NULL
factor	NULL
,	NULL
and	NULL
epidermal	NULL
growth	NULL
factor	NULL
(	NULL
8	NULL
,	NULL
9	NULL
)	NULL
.	NULL

The	NULL
absence	NULL
of	NULL
Stat1	NULL
activity	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
neutralizing	NULL
anti-IFN-y	NULL
antibodies	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
A	NULL
)	NULL
suggests	NULL
that	NULL
IFN-y	NULL
may	NULL
be	NULL
the	NULL
responsible	NULL
cytokine	NULL
.	NULL

However	NULL
,	NULL
persistence	NULL
of	NULL
Stat1	NULL
activity	NULL
over	NULL
several	NULL
days	NULL
would	NULL
be	NULL
atypical	NULL
after	NULL
IFN-y	NULL
ac-tivation	NULL
,	NULL
and	NULL
culture	NULL
supernatants	NULL
contained	NULL
very	NULL
low	NULL
levels	NULL
of	NULL
IFN-y	NULL
immuno-	NULL
and	NULL
bioactivity	NULL
(	NULL
Ivashkiv	NULL
,	NULL
L.	NULL
B.	NULL
,	NULL
unpublished	NULL
data	NULL
)	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
IFN-y	NULL
may	NULL
act	NULL
indirectly	NULL
or	NULL
that	NULL
alternative	NULL
mechanisms	NULL
,	NULL
such	NULL
as	NULL
regulation	NULL
of	NULL
Stat1	NULL
de-phosphorylation	NULL
,	NULL
may	NULL
be	NULL
important	NULL
.	NULL

Our	NULL
previous	NULL
work	NULL
showed	NULL
that	NULL
SFs	NULL
directly	NULL
activate	NULL
,	NULL
in	NULL
monocytes	NULL
,	NULL
a	NULL
DNA-binding	NULL
complex	NULL
that	NULL
contains	NULL
Stat3	NULL
but	NULL
not	NULL
Statl	NULL
(	NULL
17	NULL
)	NULL
.	NULL

The	NULL
new	NULL
results	NULL
demonstrate	NULL
that	NULL
SFs	NULL
use	NULL
a	NULL
different	NULL
mechanism	NULL
,	NULL
namely	NULL
,	NULL
inhibition	NULL
of	NULL
Stat1	NULL
,	NULL
to	NULL
achieve	NULL
a	NULL
similar	NULL
skewing	NULL
of	NULL
the	NULL
balance	NULL
of	NULL
transcriptional	NULL
activity	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

Stat3	NULL
binds	NULL
weakly	NULL
to	NULL
the	NULL
Stat1	NULL
target	NULL
sequences	NULL
in	NULL
several	NULL
promoters	NULL
and	NULL
does	NULL
not	NULL
activate	NULL
transcription	NULL
of	NULL
promoters	NULL
containing	NULL
these	NULL
sites	NULL
in	NULL
cotransfection	NULL
assays	NULL
(	NULL
reference	NULL
26	NULL
;	NULL
Zhong	NULL
,	NULL
Z.	NULL
,	NULL
unpublished	NULL
data	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
SF-treated	NULL
lymphocytes	NULL
will	NULL
probably	NULL
express	NULL
Stat3	NULL
target	NULL
genes	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
expression	NULL
of	NULL
genes	NULL
whose	NULL
transcription	NULL
depends	NULL
on	NULL
Statl	NULL
.	NULL

The	NULL
altered	NULL
balance	NULL
of	NULL
Stat3	NULL
and	NULL
Stat1	NULL
transcriptional	NULL
activity	NULL
correlates	NULL
well	NULL
with	NULL
the	NULL
altered	NULL
balance	NULL
of	NULL
cytokine	NULL
production	NULL
and	NULL
was	NULL
also	NULL
detected	NULL
in	NULL
cells	NULL
from	NULL
inflamed	NULL
joints	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
B	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
a	NULL
role	NULL
for	NULL
Stat1l	NULL
and	NULL
Stat3	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
development	NULL
of	NULL
Th	NULL
phenotype	NULL
and	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
inflammatory	NULL
synovitis	NULL
.	NULL

We	NULL
thank	NULL
Drs	NULL
.	NULL

Jim	NULL
Darnell	NULL
and	NULL
Kendall	NULL
Smith	NULL
for	NULL
helpful	NULL
discussions	NULL
,	NULL
and	NULL
Drs	NULL
.	NULL

Jim	NULL
Darnell	NULL
,	NULL
Jeff	NULL
Edberg	NULL
,	NULL
and	NULL
Patricia	NULL
Finn	NULL
for	NULL
critical	NULL
review	NULL
of	NULL
the	NULL
manuscript	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
grant	NULL
KO8	NULL
AR-01852	NULL
and	NULL
an	NULL
Arthritis	NULL
Investigator	NULL
Award	NULL
,	NULL
both	NULL
to	NULL
L.	NULL
B.	NULL
Ivashkiv	NULL
.	NULL

Address	NULL
correspondence	NULL
to	NULL
Dr.	NULL
Lionel	NULL
B.	NULL
Ivashkiv	NULL
,	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
Hospital	NULL
for	NULL
Special	NULL
Surgery	NULL
,	NULL
535	NULL
East	NULL
70th	NULL
Street	NULL
,	NULL
New	NULL
York	NULL
,	NULL
NY	NULL
10021	NULL
.	NULL

Received	NULL
for	NULL
publication	NULL
8	NULL
May	NULL
1995	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
19	NULL
June	NULL
1995	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Romagnani	NULL
,	NULL
S.	NULL
1994	NULL
.	NULL

Lymphokine	NULL
production	NULL
by	NULL
human	NULL
T	NULL
cells	NULL
in	NULL
disease	NULL
states	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

12:227-257	NULL
.	NULL

2	NULL
.	NULL

Kuchroo	NULL
,	NULL
VJ	NULL
.	NULL

,	NULL
M.B	NULL
.	NULL

Das	NULL
,	NULL
J.A	NULL
.	NULL

Brown	NULL
,	NULL
A.M.	NULL
Ranger	NULL
,	NULL
S.S.	NULL
Zamvil	NULL
,	NULL
R.A.	NULL
Sobel	NULL
,	NULL
HL	NULL
.	NULL

Weiner	NULL
,	NULL
N.	NULL
Nabavi	NULL
,	NULL
and	NULL
LH	NULL
.	NULL

Glimcher	NULL
.	NULL

1995	NULL
.	NULL

B7-1	NULL
and	NULL
B7-2	NULL
costimulatory	NULL
molecules	NULL
activate	NULL
differentially	NULL
the	NULL
Th1/Th2	NULL
developmental	NULL
pathways	NULL
:	NULL
application	NULL
to	NULL
autoimmune	NULL
disease	NULL
therapy	NULL
.	NULL

Cell	NULL
.	NULL

80:707-718	NULL
.	NULL

3	NULL
.	NULL

Williams	NULL
,	NULL
R.O	NULL
.	NULL

,	NULL
L.J	NULL
.	NULL

Mason	NULL
,	NULL
M.	NULL
Feldmann	NULL
,	NULL
and	NULL
R.N	NULL
.	NULL

Maini	NULL
.	NULL

1994	NULL
.	NULL

Synergy	NULL
between	NULL
anti-CD4	NULL
and	NULL
anti-TNF	NULL
in	NULL
the	NULL
amelioration	NULL
of	NULL
established	NULL
collagen-induced	NULL
arthritis	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

91:2762-2766	NULL
.	NULL

4	NULL
.	NULL

Sadlack	NULL
,	NULL
B.	NULL
,	NULL
H.	NULL
Mertz	NULL
,	NULL
H.	NULL
Schorle	NULL
,	NULL
A.	NULL
Schimpel	NULL
,	NULL
A.C.	NULL
Feller	NULL
,	NULL
and	NULL
I.	NULL
Horak	NULL
.	NULL

1993	NULL
.	NULL

Ulcerative	NULL
colitis-like	NULL
disease	NULL
in	NULL
mice	NULL
with	NULL
a	NULL
disrupted	NULL
interleukin-2	NULL
gene	NULL
.	NULL

Cell	NULL
.	NULL

75:253-261	NULL
.	NULL

5	NULL
.	NULL

Wen	NULL
,	NULL
L.	NULL
,	NULL
SJ	NULL
.	NULL

Roberts	NULL
,	NULL
J.L	NULL
.	NULL

Viney	NULL
,	NULL
F.S	NULL
.	NULL

Wong	NULL
,	NULL
C.	NULL
Mallick	NULL
,	NULL
1830	NULL
R.C	NULL
.	NULL

Findly	NULL
,	NULL
Q.	NULL
Peng	NULL
,	NULL
J.E	NULL
.	NULL

Craft	NULL
,	NULL
MJ	NULL
.	NULL

Owen	NULL
,	NULL
and	NULL
A.C.	NULL
Hay-day	NULL
.	NULL

1994	NULL
.	NULL

Immunoglobulin	NULL
synthesis	NULL
and	NULL
generalized	NULL
au-toimmunity	NULL
in	NULL
mice	NULL
congenitally	NULL
deficient	NULL
in	NULL
«	NULL
B	NULL
(	NULL
+	NULL
)	NULL
T	NULL
cells	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

369:654-658	NULL
.	NULL

6	NULL
.	NULL

Cheevers	NULL
,	NULL
WP	NULL
.	NULL

,	NULL
LL	NULL
.	NULL

Perry	NULL
,	NULL
M.J.	NULL
Wilkerson	NULL
,	NULL
and	NULL
G.A	NULL
.	NULL

Hul-linger	NULL
.	NULL

1994	NULL
.	NULL

Type	NULL
2	NULL
immune	NULL
responses	NULL
to	NULL
viral	NULL
antigens	NULL
in	NULL
lentivirus	NULL
induced	NULL
arthritis	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

37:8397	NULL
.	NULL

(	NULL
Abstr	NULL
.	NULL
)	NULL

7	NULL
.	NULL

Seder	NULL
,	NULL
R.A.	NULL
,	NULL
and	NULL
W.E	NULL
.	NULL

Paul	NULL
.	NULL

1994	NULL
.	NULL

Acquisition	NULL
of	NULL
lympho-kine-producing	NULL
phenotype	NULL
by	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

12:635-673	NULL
.	NULL

8	NULL
.	NULL

Darnell	NULL
,	NULL
J.E	NULL
.	NULL

,	NULL
Jr.	NULL
,	NULL
LM	NULL
.	NULL

Kerr	NULL
,	NULL
and	NULL
G.R	NULL
.	NULL

Stark	NULL
.	NULL

1994	NULL
.	NULL

Jak-STAT	NULL
pathways	NULL
and	NULL
transcriptional	NULL
activation	NULL
in	NULL
response	NULL
to	NULL
IFNs	NULL
and	NULL
other	NULL
extracellular	NULL
signaling	NULL
proteins	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

264:1415-1421	NULL
.	NULL

9	NULL
.	NULL

Taniguchi	NULL
,	NULL
T.	NULL
1995	NULL
.	NULL

Cytokine	NULL
signaling	NULL
through	NULL
nonreceptor	NULL
Inhibition	NULL
of	NULL
IFN-y	NULL
and	NULL
Stat1	NULL
by	NULL
Synovial	NULL
Fluids	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18.	NULL
protein	NULL
tyrosine	NULL
kinases	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

268:251-255	NULL
.	NULL

Klingmuller	NULL
,	NULL
U.	NULL
,	NULL
U.	NULL
Lorenz	NULL
,	NULL
L.C	NULL
.	NULL

Cantley	NULL
,	NULL
B.G	NULL
.	NULL

Neel	NULL
,	NULL
and	NULL
H.F.	NULL
Lodish	NULL
.	NULL

1995	NULL
.	NULL

Specific	NULL
recruitment	NULL
of	NULL
SH-PTP1	NULL
to	NULL
the	NULL
erythropoietin	NULL
receptor	NULL
causes	NULL
inactivation	NULL
of	NULL
JAK2	NULL
and	NULL
termination	NULL
of	NULL
proliferative	NULL
signals	NULL
.	NULL

Cell	NULL
.	NULL

80:729-738	NULL
.	NULL

Zhang	NULL
,	NULL
X.	NULL
,	NULL
J.	NULL
Blenis	NULL
,	NULL
H.-C.	NULL
Li	NULL
,	NULL
C.	NULL
Schindler	NULL
,	NULL
and	NULL
S.	NULL
Chen-Kiang	NULL
.	NULL

1995	NULL
.	NULL

Requirement	NULL
for	NULL
serine	NULL
phosphorylation	NULL
for	NULL
formation	NULL
of	NULL
STAT-promoter	NULL
complexes	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

267:1990-1994	NULL
.	NULL

Feldman	NULL
,	NULL
G.M	NULL
.	NULL

,	NULL
E.J	NULL
.	NULL

Chuang	NULL
,	NULL
and	NULL
D.S	NULL
.	NULL

Finbloom	NULL
.	NULL

1995	NULL
.	NULL

IgG	NULL
immune	NULL
complexes	NULL
inhibit	NULL
IFNy-induced	NULL
transcription	NULL
of	NULL
the	NULL
FcyRI	NULL
gene	NULL
in	NULL
human	NULL
monocytes	NULL
by	NULL
preventing	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
the	NULL
p91	NULL
(	NULL
Stat1	NULL
)	NULL
transcription	NULL
factor	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

154:318-325	NULL
.	NULL

Firestein	NULL
,	NULL
G.S	NULL
.	NULL

1994	NULL
.	NULL

Rheumatoid	NULL
arthritis	NULL
and	NULL
pannus	NULL
.	NULL

In	NULL
Rheumatology	NULL
.	NULL

J.H	NULL
.	NULL

Klippel	NULL
and	NULL
P.A	NULL
.	NULL

Dieppe	NULL
,	NULL
editors	NULL
.	NULL

Mosby-Year	NULL
Book	NULL
Europe	NULL
Ltd.	NULL
,	NULL
London	NULL
.	NULL

1-30	NULL
.	NULL

Katsikis	NULL
,	NULL
P.D	NULL
.	NULL

,	NULL
C.-Q	NULL
.	NULL

Chu	NULL
,	NULL
F.M	NULL
.	NULL

Brennan	NULL
,	NULL
RN	NULL
.	NULL

Maini	NULL
,	NULL
and	NULL
M.	NULL
Feldmann	NULL
.	NULL

1994	NULL
.	NULL

Immunoregulatory	NULL
role	NULL
of	NULL
interleukin	NULL
10	NULL
in	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

179:1517-1527	NULL
.	NULL

Firestein	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
N.	NULL
Zvaifler	NULL
.	NULL

1987	NULL
.	NULL

Peripheral	NULL
blood	NULL
and	NULL
synovial	NULL
fluid	NULL
monocyte	NULL
activation	NULL
in	NULL
inflammatory	NULL
arthritis	NULL
.	NULL

IIL	NULL
.	NULL

Low	NULL
levels	NULL
of	NULL
synovial	NULL
fluid	NULL
and	NULL
synovial	NULL
tissue	NULL
interferon	NULL
suggest	NULL
that	NULL
y-interferon	NULL
is	NULL
not	NULL
the	NULL
primary	NULL
macrophage	NULL
activating	NULL
factor	NULL
.	NULL

Arthritis	NULL
&	NULL
Rheum	NULL
.	NULL

30:864-871	NULL
.	NULL

Feldmann	NULL
,	NULL
M.	NULL
,	NULL
F.M	NULL
.	NULL

Brennan	NULL
,	NULL
D.	NULL
Chantry	NULL
,	NULL
C.	NULL
Haworth	NULL
,	NULL
M.	NULL
Turner	NULL
,	NULL
P.	NULL
Katsikis	NULL
,	NULL
M.	NULL
Londei	NULL
,	NULL
E.	NULL
Abney	NULL
,	NULL
G.	NULL
Buchan	NULL
,	NULL
K.	NULL
Barret	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1991	NULL
.	NULL

Cytokine	NULL
assays	NULL
:	NULL
role	NULL
in	NULL
evaluation	NULL
of	NULL
the	NULL
pathogenesis	NULL
of	NULL
autoimmunity	NULL
.	NULL

Immunol	NULL
.	NULL

Rev	NULL
.	NULL

119:105-123	NULL
.	NULL

Sengupta	NULL
,	NULL
TK	NULL
.	NULL

,	NULL
A.	NULL
Chen	NULL
,	NULL
Z.	NULL
Zhong	NULL
,	NULL
J.E	NULL
.	NULL

Darnell	NULL
,	NULL
Jr.	NULL
,	NULL
and	NULL
LL.B	NULL
.	NULL

Ivashkiv	NULL
.	NULL

1995	NULL
.	NULL

Activation	NULL
of	NULL
monocyte	NULL
effector	NULL
genes	NULL
and	NULL
STAT	NULL
family	NULL
transcription	NULL
factors	NULL
by	NULL
inflammatory	NULL
synovial	NULL
fluid	NULL
is	NULL
independent	NULL
of	NULL
interferon	NULL
gamma	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

181:1015-1025	NULL
.	NULL

Zhong	NULL
,	NULL
Z.	NULL
,	NULL
Z.	NULL
Wen	NULL
,	NULL
and	NULL
J.E	NULL
.	NULL

Darnell	NULL
,	NULL
Jr.	NULL
1994	NULL
.	NULL

Stat3	NULL
:	NULL
a	NULL
STAT	NULL
family	NULL
member	NULL
activated	NULL
by	NULL
tyrosine	NULL
phosphorylation	NULL
in	NULL
response	NULL
to	NULL
epidermal	NULL
growth	NULL
factor	NULL
and	NULL
interleukin-6	NULL
.	NULL

Science	NULL
1831	NULL
Wang	NULL
et	NULL
al	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

264:95-98	NULL
.	NULL

Cope	NULL
,	NULL
A.P	NULL
.	NULL

,	NULL
and	NULL
FM	NULL
.	NULL

Brennan	NULL
.	NULL

1992	NULL
.	NULL

Cytokine	NULL
measurements	NULL
in	NULL
biological	NULL
fluids	NULL
.	NULL

Brit	NULL
.	NULL

J.	NULL
Rheum	NULL
.	NULL

31:721-724	NULL
.	NULL

D'Andrea	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
Aste-Amezaga	NULL
,	NULL
N.M.	NULL
Valiante	NULL
,	NULL
X.	NULL
Ma	NULL
,	NULL
M.	NULL
Kubin	NULL
,	NULL
and	NULL
G.	NULL
Trinchieri	NULL
.	NULL

1993	NULL
.	NULL

Interleukin	NULL
10	NULL
(	NULL
IL~10	NULL
)	NULL
inhibits	NULL
human	NULL
lymphocyte	NULL
interferon	NULL
y	NULL
production	NULL
by	NULL
suppressing	NULL
natural	NULL
killer	NULL
cell	NULL
stimulatory	NULL
factor/IL-12	NULL
synthesis	NULL
in	NULL
accessory	NULL
cells	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

178:1041-1048	NULL
.	NULL

Jiang	NULL
,	NULL
C.K	NULL
.	NULL

,	NULL
S.	NULL
Flanagan	NULL
,	NULL
M.	NULL
Ohtsuki	NULL
,	NULL
K.	NULL
Shuai	NULL
,	NULL
LM	NULL
.	NULL

Freed-berg	NULL
,	NULL
and	NULL
M.	NULL
Blumenberg	NULL
.	NULL

1994	NULL
.	NULL

Disease-activated	NULL
transcription	NULL
factor	NULL
:	NULL
allergic	NULL
reactions	NULL
in	NULL
human	NULL
skin	NULL
cause	NULL
nuclear	NULL
translocation	NULL
of	NULL
STAT-91	NULL
and	NULL
induce	NULL
synthesis	NULL
of	NULL
keratin	NULL
K17	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:4759-4769	NULL
.	NULL

Hsieh	NULL
,	NULL
C.S	NULL
.	NULL

,	NULL
S.E	NULL
.	NULL

Macatonia	NULL
,	NULL
C.S	NULL
.	NULL

Tripp	NULL
,	NULL
S.F	NULL
.	NULL

Wolf	NULL
,	NULL
A.	NULL
O'Garra	NULL
,	NULL
and	NULL
K.M	NULL
.	NULL

Murphy	NULL
.	NULL

1993	NULL
.	NULL

Development	NULL
of	NULL
TH1	NULL
CD4*	NULL
T	NULL
cells	NULL
through	NULL
IL-12	NULL
produced	NULL
by	NULL
Listeria-induced	NULL
macro-phages	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

260:547-549	NULL
.	NULL

Reitamo	NULL
,	NULL
S.	NULL
,	NULL
A.	NULL
Remitz	NULL
,	NULL
K.	NULL
Tamai	NULL
,	NULL
and	NULL
J.	NULL
Vitto	NULL
.	NULL

1994	NULL
.	NULL

Inter-leukin~10	NULL
modulates	NULL
type	NULL
I	NULL
collagen	NULL
and	NULL
matrix	NULL
metallopro-tease	NULL
gene	NULL
expression	NULL
in	NULL
cultured	NULL
human	NULL
skin	NULL
fibroblasts	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

94:2489-2492	NULL
.	NULL

Armant	NULL
,	NULL
M.	NULL
,	NULL
H.	NULL
Ishihara	NULL
,	NULL
M.	NULL
Rubio	NULL
,	NULL
G.	NULL
Delespesse	NULL
,	NULL
and	NULL
M.	NULL
Sarfati	NULL
.	NULL

1994	NULL
.	NULL

Regulation	NULL
of	NULL
cytokine	NULL
production	NULL
by	NULL
soluble	NULL
CD23	NULL
:	NULL
costimulation	NULL
of	NULL
interferon	NULL
y	NULL
secretion	NULL
and	NULL
triggering	NULL
of	NULL
tumor	NULL
necrosis	NULL
factor	NULL
«	NULL
release	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

180:1005-1011	NULL
.	NULL

Rothstein	NULL
,	NULL
TL	NULL
.	NULL

,	NULL
JKM	NULL
.	NULL

Wang	NULL
,	NULL
D.J	NULL
.	NULL

Panka	NULL
,	NULL
LC	NULL
.	NULL

Foote	NULL
,	NULL
Z.	NULL
Wang	NULL
,	NULL
B.	NULL
Stanger	NULL
,	NULL
H.	NULL
Cui	NULL
,	NULL
S.-T.	NULL
Ju	NULL
,	NULL
and	NULL
A.	NULL
Marshak-Roth-stein	NULL
.	NULL

1995	NULL
.	NULL

Protection	NULL
against	NULL
fas-dependent	NULL
Thi-~mediated	NULL
apoptosis	NULL
by	NULL
antigen	NULL
engagement	NULL
in	NULL
B	NULL
cells	NULL
,	NULL
Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

374:163-165	NULL
.	NULL

Seidel	NULL
,	NULL
HM	NULL
.	NULL

,	NULL
LH	NULL
.	NULL

Milocco	NULL
,	NULL
P.	NULL
Lamb	NULL
,	NULL
J.E	NULL
.	NULL

Darnell	NULL
,	NULL
Jr.	NULL
,	NULL
R.B	NULL
.	NULL

Stein	NULL
,	NULL
and	NULL
J.	NULL
Rosen	NULL
.	NULL

1995	NULL
.	NULL

Spacing	NULL
of	NULL
palindromic	NULL
half	NULL
sites	NULL
as	NULL
a	NULL
determinant	NULL
of	NULL
selective	NULL
STAT	NULL
(	NULL
signal	NULL
transducers	NULL
and	NULL
activators	NULL
of	NULL
transcription	NULL
)	NULL
DNA	NULL
binding	NULL
and	NULL
transcriptional	NULL
ac-tivity	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

92:3041-3045	NULL
.	NULL

